

1 **Journal: *PLoS Pathogens***

2

3 **Full title:**

4 **Distinct molecular targets for macrocyclic lactone and isoxazoline insecticides in the**
5 **human louse: new prospects for the treatment of pediculosis**

6

7 **Short title:**

8 **Molecular targets of insecticides in the human louse**

9

10 Nicolas Lamassiaude¹, Berthine Toubate², Cédric Neveu¹, Pierre Charnet³, Catherine Dupuy²,

11 Françoise Debierre-Grockiego², Isabelle Dimier-Poisson^{2,*} and Claude L. Charvet^{1,*}

12

13 ¹INRAE, Université de Tours, ISP, F-37380, Nouzilly, France

14 ²Université de Tours, INRAE, ISP, F-37000, Tours, France

15 ³Institut des Biomolécules Max Mousseron, UMR5247, CNRS, Université de Montpellier,
16 34095 Montpellier, France

17

18 Co-corresponding authors:

19 *claude.charvet@inrae.fr (CLC) ORCID iD: [0000-0002-0596-6598](https://orcid.org/0000-0002-0596-6598)

20 Tel: +33 247427567

21 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement

22 UMR1282 - Infectiologie et Santé Publique

23 Centre de Recherche Val de Loire

24 37380 Nouzilly, France

25

26 *isabelle.poisson@univ-tours.fr (IDP) ORCID iD: [0000-0001-8917-4493](https://orcid.org/0000-0001-8917-4493)

27 Tel: +33 247367183

28 Université de Tours

29 UMR1282 - Infectiologie et Santé Publique

30 37000 Tours, France

31

32

33 **Abstract**

34

35 **Background**

36 Control of infestation by cosmopolitan lice (*Pediculus humanus*) is increasingly difficult due to
37 the transmission of resistant parasites to pediculicides. However, since the targets for
38 pediculicides have not been identified in human lice so far, their mechanism of action remain
39 largely unknown. The macrocyclic lactone, ivermectin is active against a broad range of insects
40 including human lice. Isoxazolines are a recent new chemical class targeting the γ -
41 aminobutyric acid (GABA) receptor made of the α -resistant to dieldrin (RDL) subunit and
42 exhibiting a strong insecticidal potential. Here, we addressed the pediculicidal potential of
43 isoxazolines and deciphered the molecular targets of ivermectin and the novel ectoparasiticide
44 lotilaner in the human body louse species *Pediculus humanus humanus*.

45 **Methods and findings**

46 Using toxicity bioassays, we showed that fipronil, ivermectin and lotilaner are efficient
47 pediculicides on adult lice. The RDL (Phh-RDL) and glutamate-gated chloride channel subunits
48 (Phh-GluCl) were cloned and characterized by two-electrode voltage clamp electrophysiology
49 in *Xenopus laevis* oocytes. Phh-RDL and Phh-GluCl formed functional homomeric receptors
50 respectively gated by GABA and L-glutamate with EC_{50} values of 6.4 μ M and 9.3 μ M.
51 Importantly, ivermectin displayed a super agonist action on Phh-GluCl whereas Phh-RDL
52 receptors were weakly affected. Reversally, lotilaner strongly inhibited the GABA-evoked
53 currents in Phh-RDL with an IC_{50} value 0.5 μ M, whereas it had no effect on Phh-GluCl.

54 **Conclusions**

55 We report here for the first time the pediculicidal potential of isoxazolines and reveal the distinct
56 mode of action of ivermectin and lotilaner on GluCl and RDL channels from human lice. These
57 results emphasize the clear repurposing future of the isoxazoline drug class to provide new
58 pediculicidal agents to tackle resistant-lice infestations in humans.

59

60 **Keywords:**

61 human body louse, ivermectin, GABA receptor, RDL, glutamate-gated chloride channel,
62 isoxazoline, lotilaner, pediculicide, xenopus oocyte, mode of action, insecticide, *Pediculus*
63 *humanus humanus*

64

65

66 **Autorship summary**

67

68 **Why was this study done?**

69 Human cosmopolitan lice are responsible for pediculosis, which represent a significant public
70 health concern. Resistant lice against insecticides and lack of safety of the treatments for
71 human and environment is a growing issue worldwide. Here we investigated the efficacy on
72 lice of the classical macrocyclic lactone drug, ivermectin, and the novel isoxazoline drug,
73 lotilaner. This study was done to decipher their mode of action at the molecular and funtional
74 levels in order to propose new strategies to control lice infestation.

75 **What did the researchers do and find?**

76 Our bioassay results indicate that ivermectin and lotilaner were potent at killing human adult
77 lice, with lotilaner showing a higher efficacy than ivermectin. Furthermore, we identified and
78 pharmacologically characterized the first glutamate- and GABA-gated chloride channels ever
79 described in human lice yet. Mechanistically, our molecular biology and electrophysiology
80 findings demonstrate that ivermectin acted preferentially at glutamate channels while lotilaner
81 specifically targeted GABA channels.

82 **What do these findings mean?**

83 These results provide new insights in the understanding of the insecticide mode of action and
84 highlight the isoxazolines as a new drug-repurposing opportunity for pest control strategies.

85

86

87

88 Introduction

89 Lice are spread throughout the world in both low- and high-income countries, with
90 heterogenous prevalence depending on the geographical area [1, 2]. Pediculosis prevailing
91 among school age children and homeless persons represents major economic, social but also
92 public health concerns [3-8]. Human lice include the body louse *Pediculus humanus humanus*
93 and the head louse *Pediculus humanus capitis* (order: *Phthiraptera*: Pediculidae). Both species
94 are obligate blood feeding ectoparasites, living in clothes and in the scalp area, respectively
95 [9]. Despite morphological, physiological and ecological differences, genetic studies showed
96 that head and body lice have almost the same genomic and transcriptomic contents [9-11].
97 Furthermore, body lice are vectors of the pathogenic bacteria *Bartonella quintana*, *Borrelia*
98 *recurrentis* and *Rickettsia prowazekii*, responsible for trench fever, louse-borne relapsing fever
99 and epidemic typhus, respectively [4]. The control of lice infestation remains increasingly
100 difficult due to the mode of transmission and the relative unreliable efficacy of the available
101 treatments [12]. Even though silicon-based suffocating products are widely used nowadays,
102 their efficacy largely depends on the respect of their application and is limited against the nits
103 [13]. Chemical insecticides such as organochloride (lindane), organophosphates (malathion),
104 carbamates (carbaryl) and pyrethroids (pyrethrins and synthetic permethrin), which are the first
105 line treatments recommended by the Centers for Disease Control and Prevention and by the
106 American Academy of Pediatrics, have been widely used to control lice [14, 15]. They have
107 been proposed to inhibit γ -aminobutyric acid (GABA)-gated chloride channels,
108 acetylcholinesterase and voltage-gated sodium channels, respectively, leading to the paralysis
109 of the parasite. However, louse resistance to these products has been widely reported [16-19]
110 as well as neurotoxic effects in children and toxicity on the environment [20-25]. Because
111 macrocyclic lactones (MLs) are broad-spectrum neuroactive insecticides, acaricides and
112 nematicides used to treat and prevent endo- and ectoparasites of humans and animals [26],
113 ivermectin (a derivate of the ML avermectins) has emerged as a promising pediculicide and
114 quickly became the recommended molecule for the control of body lice [27-29]. In
115 invertebrates, ivermectin inhibits glutamate-gated chloride channels (GluCl) leading to a
116 reduction in motor activity, paralysis and death. However, the molecular basis for the action of
117 ivermectin in louse is unknown. Recently, treatment failures of ivermectin against lice were
118 observed [30, 31]. In that respect, there is an urgent need to identify new druggable targets
119 and develop new pediculicidal compounds.

120 Cys-loop ligand-gated ion channels (LGICs) are the major pharmacological targets of
121 insecticides [32]. Among LGICs, the GluCl are found at inhibitory synapses of the nervous
122 system exclusively in invertebrates [33], while γ -aminobutyric acid (GABA) is the main
123 inhibitory neurotransmitter in nerves and muscles in both vertebrates and invertebrates. GluCl

124 and GABA receptors are constituted by the oligomerization of five identical or different subunits
125 around a central pore [34]. In arthropods, the finding that the insecticidal activity of avermectins
126 is mainly mediated by the GluCl_s was first achieved in the model insect *Drosophila*
127 *melanogaster* [35]. For the GABA channels (GABA_ACl_s), the screening for mutant flies that
128 survive exposure to the insecticides dieldrin and fipronil, allowed the identification of the
129 *resistant to dieldrin* gene or *rdl* [36]. When heterologously expressed in *Xenopus laevis*
130 oocytes, the GluCl and RDL subunits formed functional homomeric glutamate-gated and
131 GABA-gated chloride channels, respectively [35, 37]. GluCl and RDL subunits were
132 subsequently described in many other insect species although few of them were functionally
133 assayed *in vitro*. Mutations in the GluCl subunit confers resistance to avermectins, whereas
134 resistance to dieldrin, fipronil and picrotoxinin was shown to be associated to mutations in the
135 RDL subunit using functional *in vitro* and *in vivo* experiments [32].

136 Interestingly, new synthetic molecules from the isoxazoline chemical class were recently
137 proven to be effective ectoparasiticides against fleas and ticks [38]. The isoxazoline
138 insecticides include fluralaner, afoxolaner, sarolaner and lotilaner [39-42]. They were shown
139 to act as potent non-competitive antagonists of GABA_ACl_s from *D. melanogaster* as well as the
140 cat flea *Ctenocephalides felis* and the livestock tick *Rhipicephalus microplus* by molecular
141 experiments and voltage-clamp electrophysiology. In addition, these compounds were efficient
142 at blocking GABA-elicited currents from dieldrin- and fipronil-resistant channels. Recent
143 studies on the actions of these compounds on cloned GABA_ACl_s have accounted for their higher
144 selectivity for insect over vertebrate receptors [42, 43]. Compounds from the isoxazoline group
145 are now considered as the next generation of broad-spectrum insecticides effective against
146 veterinary, agricultural, sanitary and stored product pests from eleven arthropod orders [44].
147 However, the pediculicidal activity of isoxazolines, the identification of the target ion channels
148 in lice and their potential use for human health have not been investigated so far.

149 The objectives of our study were to decipher the molecular targets of ivermectin and lotilaner
150 in the human body louse species *Pediculus humanus humanus* (Phh). In the present paper,
151 we describe in the human body louse: the *in vivo* pediculicidal activity, the target identification
152 and *in vitro* mechanism of action of the old phenylpyrazole insecticide, fipronil, the recent ML
153 insecticide, ivermectin, and the novel isoxazoline, lotilaner. For this, we identified the human
154 body louse orthologues of the GluCl and RDL subunit genes and subsequently achieved their
155 respective functional characterizations in *Xenopus* oocytes using two-electrode voltage-clamp.
156 We found that the Phh-GluCl and Phh-RDL subunits give rise to glutamate-gated and GABA-
157 gated homomeric channels having distinct pharmacological properties. Hence, we provide
158 mechanistic insights for a distinct mode of action of ivermectin and lotilaner. In the context of

159 drug-resistance, this study highlights the pediculicidal potential of lotilaner in a drug-
160 repurposing attempt of new strategies to control human louse infestations.

161

162 **Results**

163 ***In vivo* toxicity tests of ivermectin and lotilaner on lice and nits**

164 In order to determine the efficacy of selected insecticides, we first performed insecticide
165 exposure tests on laboratory-reared human adult body lice and nits (**Fig. 1A**). Briefly, lice were
166 incubated with ivermectin, fipronil, picrotoxin and lotilaner at different concentrations. The
167 effects of the compounds on louse survival and immobilization (knockdown) were
168 subsequently analyzed at four timepoints (1, 2, 3, and 24 hours). After 24h, there was 4.5%
169 mortality in the groups of lice treated with 1% DMSO that was used to dissolve the different
170 compounds (**Fig. 1B**). Similarly, 100 μ M picrotoxin was not efficient to kill the lice after 24h
171 whereas 91% of the lice were killed or immobilized with exposure to 100 μ M fipronil. In our
172 experiments, fipronil was used as a positive control and this result corroborated previous
173 bioassays in the literature [45]. As expected, ivermectin was more efficient than fipronil, since
174 the death rate reached 30%, 3h after application of 100 μ M, and 100% after 24h application of
175 both 10 and 100 μ M (**Fig. 1B**). These findings confirmed the insecticide susceptible status of
176 the laboratory-reared colony used here. Strikingly, after application of 100 μ M lotilaner, the
177 number of living lice declined rapidly. Not only the application of 1 μ M lotilaner killed 14% of
178 lice at 24 h but 10 and 100 μ M lotilaner led to the death of all lice 3h after exposition (**Fig. 1B**).
179 Interestingly, when compared with other drugs, 10 μ M lotilaner was more efficient than 10 μ M
180 ivermectin and 100 μ M fipronil. Next, we analyzed the effect of 100 μ M ivermectin or lotilaner
181 on the nit hatching between six and nine days after drug application. The rate of nits hatched
182 did not differ between the ivermectin- and the lotilaner-treated nits and the negative controls
183 (water and 1% DMSO) thus revealing no effect of the two products on the nits (**Fig. 1C**).
184 Altogether, these results confirm that fipronil and ivermectin are efficient at killing human adult
185 body lice and provide the first *in vivo* evidence of a pediculicidal activity for lotilaner. These
186 data prompted us to investigate the targets of ivermectin and lotilaner at the molecular level.

187

188 **GluCl and RDL subunits are conserved in *P. humanus humanus***

189 Macrocyclic lactones and isoxazolines were previously shown to act on arthropod glutamate-
190 and GABA-gated channels. Therefore, we decided to identify and clone the respective *P.*
191 *humanus humanus* GluCl and RDL subunits through a candidate gene approach. Searches
192 for homologues of *A. mellifera* and *D. melanogaster* GluCl and RDL receptor subunits in *P.*
193 *humanus* genomic/transcriptomic databanks, allowed the identification of two independent

194 coding sequences for *Phh-GluCl* and for *Phh-rdl* for which the respective complete coding
195 sequences were obtained by RACE PCR experiments. Both louse GluCl and RDL displayed
196 the characteristic features of cys-loop LGIC subunits, including a signal peptide, an
197 extracellular N-terminal domain containing the ligand binding sites, a disulfide bond formed by
198 two cysteines that are 13 amino acid residues apart (cys-loop domain), four transmembrane
199 domains (TM1-TM4) and a large intracellular loop between TM3 and TM4 that is highly variable
200 (**Fig. 2**). Of importance is the sequence analysis of the pore selectivity filter located in the TM2
201 supporting the prediction with the signature of a chloride channel. Indeed, Phh-GluCl and Phh-
202 RDL both contain the PAR motif centered at the 0' position in the TM2 and conserved in other
203 species (universal LGIC TM2 numbering system). A proline at position -2', followed by a small
204 amino acid at position -1' like an alanine, an arginine at the 0' residue and a threonine at
205 position 13' are the hallmarks of chloride-permeable LGICs [46].

206 The full-length coding sequences for the GluCl subunits included ORFs of 1353 and 1350 pb
207 encoding proteins of 450 and 449 amino acids that were named Phh-GluCl-1 (MT321070) and
208 Phh-GluCl-2 (MT321071), respectively. The alignment of *Phh-GluCl-1* and *Phh-GluCl-2*
209 deduced amino-acid sequences is provided in **Fig. 2**. The two sequences are highly conserved
210 with 97% identity and 98% similarity and only differ by eleven amino acid substitutions and an
211 alanine insertion in the N-terminal part at position 59 in Phh-GluCl-1. (**Fig. 2** and **S1 Fig.**).
212 Noteworthy, all the amino acids involved in the glutamate binding were conserved.

213 For RDL subunits, both full-length coding sequences are 1467 nucleotide long encoding 489
214 amino acids. Phh-RDL-1 (MT321072) and Phh-RDL-2 (MT321073) share 96% identity and
215 98% similarity, only differing by 20 amino acid substitutions including 17 amino acid changes
216 located in the extracellular N-terminal region between the signal peptide and the TM1 (**Fig. 2**
217 and **S2 Fig.**). Notably, none of the residues involved in the binding of GABA were subjected to
218 substitutions.

219 A distance tree analysis of *P. humanus humanus* GluCl and RDL sequences including *D.*
220 *melanogaster*, the honey bee *Apis mellifera*, the house fly *Musca domestica*, *R. microplus* and
221 the red flour beetle *Tribolium castaneum* confirmed the orthologous relationships of the louse
222 subunit sequences with their respective counterparts (**Fig. 3**). GluCl amino acid sequences
223 revealed that Phh-GluCls were found to be highly conserved, sharing 78%, 84%, 81% and
224 70% identities with the respective orthologues from *A. mellifera*, *T. castaneum*, *D.*
225 *melanogaster* and *R. microplus*. Phh-RDL-1 and 2 shared 84%, 81%, 67% and 54% identities
226 with their orthologues from *A. mellifera*, *T. castaneum*, *D. melanogaster* and *R. microplus*,
227 respectively. These observations are in accordance with the relative position of Phthiraptera
228 and Hymenoptera insect subfamilies and Acarids [47] and were further confirmed by
229 supplementary analysis including other members from the GABA and GluCl groups from

230 additional arthropod species (**S1 Fig.** and **S2 Fig.**). In the phylogeny of GABA subunits, Phh-
231 RDL-1/-2 were found to clearly cluster distinctly from the LCCH3, GRD and 8916 subunits,
232 showing that each species has inherited an ancestral gene. Altogether, the phylogenetic
233 observations support that we cloned the *P. humanus humanus* GluCl and RDL subunit
234 orthologues allowing their subsequent assessment at the functional level.

235

236 ***P. humanus humanus* GluCl and RDL subunits form functional homomeric channels in** 237 ***Xenopus oocytes***

238 In previous studies, arthropod GluCl and RDL subunits were shown to reconstitute functional
239 channels when expressed in *Xenopus oocytes* [32]. Hence, we hypothesized that the ortholog
240 subunits from *P. humanus humanus* could form functional receptors. Following the cloning of
241 two full-length coding sequences for Phh-GluCl and Phh-RDL subunits, their respective cRNAs
242 were microinjected in *X. laevis* oocytes. To investigate the receptor functionality, responses to
243 agonists were assessed by two-electrode voltage-clamp (TEVC) electrophysiology. In sharp
244 contrast with Phh-GluCl-1 and Phh-RDL-1 subunits (**Fig. 4**), injections of *Phh-GluCl-2* (n=11)
245 and *Phh-RDL-2* (n=12) cRNAs never led to recordings of glutamate- and GABA-evoked
246 currents, respectively, indicating that these subunits did not form functional receptors (**S3 Fig.**).
247 Thus, Phh-GluCl-1 and Phh-RDL-1 will be henceforth referred to as Phh-GluCl and Phh-RDL
248 in the article. When glutamate was perfused in the recording chamber, we could record fast
249 inward currents in the μA range in oocytes injected with *Phh-GluCl* (**Fig. 4A**). As expected, this
250 receptor desensitized extremely rapidly upon prolonged glutamate exposure. Then, we
251 obtained the concentration-response curve by challenging the oocytes with glutamate
252 concentrations ranging from 1 to 1000 μM . With current amplitudes normalized to the maximal
253 response to 1000 μM , we found that the glutamate EC_{50} value of Phh-GluCl was 9.3 \pm 1.3
254 μM with a Hill coefficient of 1.9 \pm 0.5 (n=5) suggesting the presence of more than one
255 glutamate binding site (**Fig. 4A-B**). When *Phh-RDL* cRNAs were injected in oocytes, the
256 application of 100 μM GABA resulted in robust currents with maximum amplitudes in the μA
257 range (**Fig. 4C**). The GABA concentration-response curve was characterized by an EC_{50} of
258 6.4 \pm 0.4 μM (n=6) with a Hill coefficient of 2.1 \pm 0.2 (n=6) suggesting the binding of more
259 than two GABA molecules (**Fig. 4C-D**). As previously shown in the literature, RDL and GluCls
260 are permeable to chloride anions [35, 37, 48-51]. Here, the TM2 amino acid sequences of Phh-
261 RDL and Phh-GluCl are respectively 100% identical with RDL and GluCls from other insect
262 species such as *A. mellifera*, *D. melanogaster*, *T. castaneum* (**Fig. 2**), suggesting they are
263 anionic receptors. In order to investigate the ion selectivity, we applied voltage-ramps to
264 oocytes expressing Phh-RDL and measured the reversal potentials for GABA-sensitive

265 currents in recording solution with varying concentrations of either chloride or sodium. Then,
266 the reversal potentials were plotted against the chloride or sodium concentration (**Fig. 4E**). In
267 the standard recording solution containing 100 mM NaCl, GABA-induced currents reversed at
268 -22.5 ± 0.8 mV ($n=10$) (**Fig. 4E**). When the extracellular chloride concentration decreased
269 from 100 to 0 mM (replacement of chloride by sodium acetate), Phh-RDL exhibited a $36.4 \pm$
270 1.2 mV shift upon a 10-fold change in the chloride concentration ($n=4$). In contrast, decreasing
271 the extracellular sodium concentration from 100 to 0 mM (replaced by tetraethylammonium
272 chloride) did not significantly shift the reversal potential (2.3 ± 0.8 mV shift per decade, $n=4$).
273 These results indicate that Phh-RDL forms a chloride permeable GABA-gated channel that
274 does not permeate sodium ions, consistently with the pore selectivity filter sequence (**Fig. 2**)
275 and RDL channels from other species [51, 52]. In summary, these findings demonstrate that
276 two novel functional homomeric receptors from the human body louse, Phh-GluCl and Phh-
277 RDL, with respectively high affinity to glutamate or GABA were reconstituted in *Xenopus*
278 oocytes.

279

280 **Differential effects of ivermectin and lotilaner on *P. humanus humanus* GluCl and RDL** 281 **channels**

282 Arthropod GluCl and RDL channels are well-known targets for insecticides [32]. In order to
283 investigate their respective insecticides sensitivities, Phh-GluCl and Phh-RDL were challenged
284 with ivermectin, lotilaner, fipronil and picrotoxin. Recordings from oocytes expressing Phh-
285 GluCl revealed that ivermectin is a potent agonist of this receptor. A slow activation of the
286 receptor was observed with application of ivermectin as low as 10 nM and large μ A currents
287 were recorded in response to 1 μ M ivermectin with an average of $86.5 \pm 8.2\%$ ($n=6$) of the 1
288 mM glutamate-elicited current (**Fig. 5A-B**). As expected, the effect of ivermectin was not
289 reversible. When applied on Phh-GluCl expressing oocytes, 1 μ M lotilaner did not elicit any
290 current and mediated no inhibitory effect on glutamate-evoked currents (**Fig. 5C**). We
291 subsequently tested the activity of selected insecticides on the Phh-RDL channel. As
292 anticipated from the literature, ivermectin, lotilaner, picrotoxin and fipronil had no agonist effect
293 (**Fig. 6 and Fig. S4**). Then, we investigated the potential antagonistic effects of the selected
294 insecticides on GABA recording traces. **Figures 6A-D and S4** illustrate results from application
295 of 100 μ M GABA before, during and after the addition of either 10 μ M or 1 μ M of insecticides,
296 respectively. When applied at 1 μ M fipronil, picrotoxin and lotilaner partially antagonized
297 GABA-evoked currents while 1 μ M ivermectin produced an almost insignificant effect (**Fig. S4**).
298 Rank order potency series for each of the Phh-RDL antagonists tested at a concentration of 1
299 μ M was as follows: lotilaner > picrotoxin \approx fipronil > ivermectin. When perfused at 10 μ M, the

300 selected insecticides decreased significantly the GABA-evoked current amplitude (**Fig. 6**).
301 Fipronil and picrotoxin blocked 92 +/- 4 % (n = 6) and 82 +/- 5 % (n = 5) of the GABA response
302 on Phh-RDL respectively (**Fig. 6A-B** and **6E-F**). Surprisingly, ivermectin acted as a weak
303 inhibitor of Phh-RDL with a partial effect of only 31 +/- 5 % (n=9) (**Fig. 6C** and **6E**). More
304 importantly, GABA responses were completely and irreversibly blocked with lotilaner as low as
305 3 μM suggesting that Phh-RDL is more sensitive to lotilaner than to the ancient insecticides
306 fipronil or picrotoxin (**Fig. 6D-F**). To characterize this effect, antagonist concentration-response
307 relationships were performed (**Fig. 6F**). Fipronil and picrotoxin antagonized Phh-RDL in a
308 concentration-dependent manner with IC_{50} values of 1.4 +/- 0.3 μM (n = 6 oocytes) and 2.8 +/-
309 1.4 μM (n = 5 oocytes), respectively. Similarly, lotilaner resulted in the most potent dose-
310 dependent inhibition of the GABA-mediated currents with an IC_{50} value of 0.5 +/- 0.3 μM (n =
311 6 oocytes). Altogether, these results demonstrate that *P. humanus humanus* GluCl and RDL
312 characterized in *Xenopus* oocytes display unique and distinct pharmacologies regarding
313 insecticides. Ivermectin acted as a strong agonist Phh-GluCl and a weak antagonist of Phh-
314 RDL, while the novel anti-ticks and fleas lotilaner was a potent and selective blocker of RDL of
315 human lice.

316

317 **Discussion**

318 **First functional characterization of LGICs from human lice**

319 In the present study, we report the first functional expression and pharmacological
320 characterization of any human louse LGICs. Indeed, despite the social and public health
321 impacts of human lice and the growing issue of resistance to pediculicides and since the
322 complete sequencing of the body louse genomes, there was to our knowledge no functional
323 characterization of any LGICs from lice so far [10, 29]. Because glutamate and GABA are
324 important neurotransmitters in the insect central nervous system and their receptors are
325 targets for insecticides, we focused our attention on glutamate- and GABA-sensitive receptors.
326 GluCl and RDL channel subtypes of LGICs have been extensively characterized in many
327 arthropod species starting with the model fruit fly *D. melanogaster* and ranging from agricultural
328 and sanitary pests to animal ectoparasites and disease vectors but also beneficial insects like
329 the honey bee [32, 33]. Here, we show that *P. humanus humanus* GluCl and RDL subunits
330 gave rise to homomeric channels when functionally expressed in *Xenopus* oocytes. This
331 experimental expression system provided a unique means to assess the pharmacological and
332 biophysical properties of these receptors. Even though two putative genes encoding
333 respectively a GluCl and a GABA receptor have been identified in the genomic database, the
334 molecular cloning of complete cDNAs revealed at least two potential full-length transcripts for

335 both candidates (i.e. Phh-GluCl-1, Phh-GluCl-2 and Phh-RDL-1, Phh-RDL-2). These
336 transcripts could either be alternative spliced isoforms or result from RNA A-to-I editing, a
337 mechanism of RNA edition described in lice [53]. In insects, alternative splicing and RNA A-to-
338 I editing are known to increased diversity of LGICs subunits [54-57]. Undoubtedly, further
339 molecular investigations at the DNA level would be required to confirm this hypothesis. Here,
340 we report that both Phh-GluCl-1 and Phh-RDL-1 can be robustly expressed in *Xenopus*
341 oocytes, whereas neither Phh-GluCl-2 nor Phh-RDL-2 subunits formed functional receptors in
342 our conditions. Interestingly, Phh-GluCl had one of the highest affinity for glutamate compared
343 to other GluCls of arthropod species, the reported EC₅₀ of which varied between 6.89 and
344 384.2 μ M [35, 43, 48-50, 58-62]. Likewise, Phh-RDL had one of the lowest EC₅₀ for GABA
345 among described insect RDL receptors showing EC₅₀ varying between 5.43 +/- 0.02 μ M in the
346 brown planthopper *Nilaparvata lugens* [63] and 445 +/- 47 μ M in the carmine spider mite
347 *Tetranychus cinnabarinus* [61] with the exception of the RDL-2 subunit (2.4 +/- 0.3 μ M) from
348 the honey bee parasite mite *Varroa destructor* [51]. Similarly, spliced variant transcripts of
349 GluCl and RDL subunits were found to give rise to functional channels in several insect
350 species, thus increasing their receptor diversity [33, 56, 57, 60, 62, 64-66]. Here, we identified
351 and characterized the first GluCl and GABA_A receptors of human lice. This study opens the
352 way for the characterization of other receptor subtypes which can also be relevant target.

353

354 **New insights into the mode of action of ivermectin on lice**

355 Despite the massive use of pediculicidal compounds during the past decades, there was to
356 our knowledge no functional characterization of their molecular targets in lice. Macrocyclic
357 lactones are widely used in both veterinary and human medicine, with ivermectin being
358 typically the recommended molecule for the control of body lice [27-29]. This broad-spectrum
359 drug is highly efficient against a wide range of pathogens including endo and ectoparasites
360 such as nematodes, acarions and insects [26]. In comparison with other pediculicides,
361 ivermectin presents some major advantages. First, it has long been recognized that it is a safe
362 pharmaceutical in human health due to low level of toxicity for mammals, in sharp contrast
363 with classical pediculicides [67]. Indeed, former drugs such as fipronil, lindane or malathion
364 are now forbidden for human use in several countries because of their toxicity and
365 environmental impact [20-25]. Second, ivermectin is currently the only molecule used as an
366 oral treatment against lice. For head lice, oral route avoids suboptimal shampoo application,
367 thus reducing the emergence and transmission of resistant lice [28, 68-70]. For body lice, oral
368 dosing is of particular interest to treat people having a limited access to basic hygiene services.

369 However, despite these remarkable advantages, ivermectin's efficacy is currently
370 compromised by the emergence of resistant lice [30, 31].

371 Here, our bioassay confirmed the pediculicidal activity of ivermectin on human body lice.
372 Furthermore, we addressed for the first time the mode of action of ivermectin at the molecular
373 level on glutamate- and GABA-gated receptors. We showed that ivermectin activated only
374 Phh-GluCl channel. In addition, ivermectin blocked the RDL receptor but with a concentration
375 10 times higher than the concentration required to fully activate Phh-GluCl. These findings
376 suggest that ivermectin do not have any effect on Phh-RDL at the dose used to treat people
377 and reveal that Phh-GluCl is its preferential target. Interestingly, functional silencing using
378 RNAi has already been shown to be an efficient and promising approach to investigate the role
379 of detoxification genes in ivermectin tolerance of human body lice [71]. In order to confirm that
380 GluCl is the main target of ivermectin in lice, it would be interesting to explore *in vivo* the
381 phenotype of *Phh-GluCl* siRNA silenced lice as previously demonstrated for abamectin in *T.*
382 *cinnabarinus* and in the crop whitefly pest *Bemisia tabaci* [61, 72]. Finally, following the recent
383 observation of GluCl single-nucleotide-polymorphisms (SNPs) in phenotypically ivermectin-
384 resistant head lice [30], our results provide a unique means to explore the molecular
385 mechanisms underlying louse resistance to ivermectin. In a further step, such
386 electrophysiology studies in *Xenopus* oocytes will enable to determine the functional relevance
387 of GluCl SNPs detected in ivermectin-resistant lice [49, 59, 73-75]. Although the putative role
388 of those SNPs are to be determined, we can reasonably assume that mutated subunits can
389 lead to GluCl altered functionality, probably resulting in ivermectin resistance. Additionally,
390 screening on ivermectin-resistant GluCl recombinantly expressed will provide a powerful tool
391 to optimize the design of new pediculicidal compounds. Further investigations are required to
392 understand the mechanisms of ivermectin resistance and to define new control strategies to
393 avoid emergence of resistance as well as preserve this molecule efficacy.

394

395 **On the mode of action of lotilaner in arthropods**

396 With the recent introduction of new generation of compounds in the isoxazoline class (e.g.
397 lotilaner), the development of detailed understanding of the actions of isoxazolines is essential.
398 Arthropod RDL channels are major targets for several old insecticidal classes including dieldrin
399 itself and fipronil [32] and they were recently shown to be the primary target for isoxazolines
400 [39-43]. Therefore, we hypothesized that they could act on RDL from *Pediculus humanus*
401 *humanus*. In addition to the pharmacological characterization of Phh-RDL and Phh-GluCl, our
402 results show that the inhibitory effects of lotilaner depend on the receptor subtype. Indeed,
403 lotilaner efficiently and selectively blocked the GABA response on Phh-RDL whereas Phh-

404 GluCl was not affected. In order to confirm these findings, it will be interesting to silence the
405 *rdl* gene using RNAi in human body lice [61]. Our results clearly demonstrated the selective
406 antagonistic action of lotilaner on RDL over GluCl channels contrary to A1443 and fluralaner,
407 which were reported to inhibit both RDL and GluCls from *M. domestica* and *R. microplus* [39,
408 43, 76]. Whether these differences might be due to the compounds themselves or the
409 pharmacological properties of receptors from different species remain to be investigated.
410 Furthermore, the amino acids implicated in the binding of lotilaner are not known yet although
411 some studies recently suggested that amino acids in the TM1 and TM3 might be critical in RDL
412 from *M. domestica* [77]. The mechanism of action of lotilaner on RDL receptors at the
413 molecular level are still to be deciphered. Likewise, further efforts are needed to better
414 understand the molecular basis of the insect selectivity of isoxazolines over vertebrate
415 channels. Contrary to homomeric arthropod RDL channels, the vertebrate GABA are
416 heteromeric channels made of different subunits. Recent studies indicated that A1443,
417 fluralaner and lotilaner were highly selective of arthropod RDL channels while poorly efficient
418 on rat brain membranes ($IC_{50} > 10 \mu M$), rat GABA channels ($IC_{50} > 30 \mu M$) and canine GABA
419 ($IC_{50} > 10 \mu M$), respectively, thus evidencing for low mammalian toxicity [39, 42, 43].
420 Resistance to isoxazolines has not been reported so far and fipronil resistance is likely not to
421 confer cross-resistance to lotilaner. Likewise, the distinct mechanisms of action for ivermectin
422 and lotilaner seem to indicate that resistance to ivermectin will not extend to lotilaner.
423 Identification of homologous genes encoding RDL subunits and investigation of new expressed
424 recombinant RDL from many other arthropod species including important insect pest species,
425 acari and crustaceans will enhance our understanding of the action of isoxazolines. The
426 potency and selectivity of isoxazolines indicate an important future for this novel class of
427 compounds.

428

429 **From dog to human: the future for isoxazoline insecticides as promising pediculicidal** 430 **candidates for drug repurposing**

431 The isoxazoline class includes a new generation of insecticidal compounds recently
432 introduced for insect chemical control. Since the discovery of isoxazolines, their insecticidal
433 spectrum has become broader to agricultural, sanitary and animal insect pests belonging to
434 eleven orders missing out the order of *Phthiraptera* [39-44]. In the present study, we
435 hypothesized that the isoxazolines could represent attractive candidate drugs to extend the
436 pharmacopeia for louse control. Among the different compounds from the isoxazoline family,
437 we selected the novel insecticide lotilaner as a model for the following reasons: first, it is
438 licensed for protection of companion animals against fleas and ticks and therefore presents a

439 reduced toxicity to mammals; second, it has a long lasting effect after a single oral
440 administration [42, 78]. In dogs, lotilaner remains active against ticks and fleas during one
441 month with an efficacy ranging from 98 to 100% [79, 80]. Here, we assessed the pediculicidal
442 potential of lotilaner against different stages of body lice. Strikingly, our bioassays on human
443 body lice demonstrated that the adulticide effect of lotilaner was higher than that of ivermectin
444 and fipronil. Whereas 10 μ M ivermectin treatment killed 100% of adult lice after 24h, we
445 obtained the same result with 10 μ M lotilaner in only 3 hours following exposure. This fast
446 activity is in accordance with the 4h-12h needed to kill ticks and fleas in lotilaner treated dogs
447 [79, 80]. In contrast, neither ivermectin nor lotilaner were found to have a pediculicidal activity
448 on nits. Based on dog data, we can speculate that a single oral dose could provide a
449 pediculicidal activity above 17 days corresponding to the complete life cycle of the human lice
450 [9, 19]. Therefore, the long lasting activity of lotilaner could overcome the absence of activity
451 on embryonated eggs and also prevent re-infestations with a single oral dose. Considering its
452 relatively benign toxicological profile for mammals along with rapid knockdown of lice, lotilaner
453 seems to be an excellent candidate drug to tackle louse infestations in humans. Nevertheless,
454 the innocuity of lotilaner towards human remains to be proven as well as its pharmacokinetics.
455 Interestingly, Miglianico *et al.* recently reported the high efficacy of two other veterinarian drugs
456 from the isoxazoline family (i.e afoxolaner and fluralaner) against a panel of insect species
457 representing major vectors for human tropical diseases [81]. Computational modelling
458 highlighted both the feasibility and the relevancy of using isoxazoline for human medication. In
459 accordance, our results strongly support isoxazoline compounds as major candidates for drug
460 repurposing alone or in co-administration with ivermectin. Indeed, new combinations of active
461 compounds have become frequent in veterinary medicine (e.g. anthelmintics). Alike
462 ivermectin, a useful feature of lotilaner is its mode of administration through oral route, which
463 is more tractable to human than topical formulations. Since ivermectin and lotilaner are efficient
464 at targeting distinct receptors, it is tempting to suggest that a combination of both drugs may
465 have a considerable potential, resulting in an additive or a synergistic effect allowing the control
466 of emerging ivermectin resistant lice and delay or overcome resistance. Such a therapeutic
467 option was recently achieved with the release of fluralaner combined with moxidectin [82, 83]
468 and sarolaner combined with selamectin on the veterinary market for small animals [84, 85].
469 Hence, it is reasonable to conclude that further investigations on the efficacy of lotilaner alone
470 or in combination with ivermectin for general use as pediculicides would be particularly
471 pertinent and justified. We hope that the results presented here contributes to an increased
472 understanding on the mechanisms behind the physiology of neurotransmission and of the
473 mode of action of the pediculicidal drugs in body lice at the functional level and will provide
474 new therapeutic strategies to ensure the sustainable and effective control of louse infestations.
475

476 **Methods**

477 **Chemical assays on body lice**

478 The colony of human body lice (*Pediculus humanus humanus*) were provided by Kosta Y.
479 Mumcuoglu from the Kuvin Center for the Study of Infectious and Tropical Diseases, Hebrew
480 University-Hadassah Medical School, Jerusalem, Israel. This laboratory-reared colony adapted
481 to rabbit blood were fed four times per week (permit number of the French Ministry for
482 Research: APAFIS#8455-2017010616224913 v3) and maintained at 30 ± 1 °C and 60-70%
483 relative humidity without exposure to any drugs [86]. Survival and immobilization (knockdown)
484 were monitored at 1, 2, 3 and 24 h after contact of 44 lice with insecticides at concentrations
485 ranging from 1 to 100 μ M or 1% DMSO. Nits (50 to 190 per condition) were incubated with
486 lotilaner or ivermectin and hatching was monitored between six and nine days. Water and
487 solution of 1 % DMSO were used as negative controls. Pictures and movies were recorded
488 with a Motic Digital Microscope 143 Series and the Motic Image Plus 3.0 software. Movies
489 were cut out with Apple inc. iMovie 10.1.6.

490 **Cloning of full-length cDNA sequences of *GluCl* and *rdl* from *Pediculus humanus*** 491 ***humanus***

492 Total RNA was extracted from 30 mg of lice (15 lice) using the Total RNA isolation Nucleospin
493 RNA kit (Macherey-Nagel) according to the manufacturer's recommendations.
494 Complementary DNA (cDNA) was synthesized using the GeneRacer kit with the SuperScript
495 III reverse transcriptase (Invitrogen) following the manufacturer's recommendations. Using the
496 *A. mellifera* and *D. melanogaster* *GluCl* and *RDL* subunit sequences as queries, tBLASTn
497 searches in NCBI (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) allowed the identification of partial
498 genomic contigs (AAZO01006897 and AAZO01005501 for *Phh-GluCl* and AAZO01005738,
499 AAZO01000267 and AAZO01000266 for *Phh-rdl*) and partial mRNA sequences
500 (XM_002429761 for *Phh-GluCl* and XM_002422861.1 for *Phh-rdl*) containing the 3' cDNA
501 ends. Primers designed on the sequences retrieved from the BLAST searches are reported in
502 **S1 Table**. Then, the corresponding 5' cDNA ends were obtained by RLM-RACE experiments
503 using the Generacer kit with two rounds of PCR as described elsewhere [87]. After the
504 identification of the cDNA 5' ends, new primers were designed. The full-length complete coding
505 sequences of *Phh-GluCl* and *Phh-rdl* were subsequently amplified by nested PCRs with the
506 proofreading Phusion High-Fidelity DNA Polymerase (Thermo Scientific) using two pairs of
507 primers. Then, PCR products were cloned into the transcription vector pTB-207 [88] using the
508 In-Fusion HD Cloning kit (Clontech) as described previously [89]. Recombinant plasmid DNA
509 was purified using EZNA Plasmid DNA Mini kit (Omega Bio-Tek) and the sequences were
510 checked (Eurofins Genomics). The novel complete coding sequences of the two *Phh-GluCl*

511 and Phh-RDL subunits were deposited to Genbank under the accession numbers MT321070
512 to MT321073. The constructions were linearized with the MspI restriction enzyme
513 (ThermoFisher) and cRNAs were synthesized *in vitro* using the mMessage mMachine T7
514 transcription kit following the manufacturer's recommendations (Ambion). Lithium chloride-
515 precipitated cRNAs were resuspended in RNase-free water and stored at -20 °C.

516 **Sequence analysis and phylogeny**

517 Signal peptide and transmembrane domain were predicted using SignalP4.1 [90] and SMART
518 [91], respectively. Deduced amino-acid sequences of Phh-GluCl and Phh-RDL were aligned
519 using the MUSCLE algorithm [92] and further processed with GeneDoc (IUBio). The
520 phylogenetic distance trees were generated on amino-acid sequences by the SeaView
521 software [93] using BioNJ Poisson parameters and bootstrap values were calculated with 1000
522 replicates as described previously [94]. The resulting trees were modified by FigTree
523 (<http://tree.bio.ed.ac.uk/software/figtree/>). The accession numbers for the protein sequences
524 mentioned in this article are: *Apis mellifera* (Ame): GluCl ABG75737, GRD AJE68942, LCCH3
525 AJE68943, RDL AJE68941, CG8916 NP_001071290; nAChR7 AJE70265; *Ctenocephalides*
526 *felis* (Cfe): RDL AHE41088; *Drosophila melanogaster* (Dme): GluCl AAC47266, GRD
527 NP_524131, LCCH3 NP_996469, RDL NP_523991, CG8916 NP_001162770; *Ixodes*
528 *scapularis* (Isc): GluCl ALF36853; *Musca domestica* (Mdo): GluCl BAD16657, RDL
529 NP_001292048; *Pediculus humanus humanus* (Phh): GluCl1 MT321070, GluCl2 MT321071,
530 RDL1 MT321072, RDL2 MT321073; *Rhipicephalus microplus* (Rmi): GluCl AHE41097, RDL
531 AHE41094; *Tetranychus urticae* (Tur): GluCl BAJ41378 and *Tribolium castaneum* (Tca): GluCl
532 NP_001107775, GRD NP_001107772, LCCH3 NP_001103251, RDL NP_001107809, 8916
533 NP_001103425.

534 **Electrophysiology in *Xenopus laevis* oocytes and data analysis**

535 Defolliculated *Xenopus laevis* oocytes were purchased from Ecocyte Bioscience and
536 maintained in incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂·2H₂O, 1 mM
537 MgCl₂·6H₂O, 5 mM HEPES, 2.5 mM C₃H₃NaO₃, pH 7.5 supplemented with penicillin 100 U/mL
538 and streptomycin 100 µg/mL) at 19 °C. Each oocyte was microinjected with 57 ng of cRNA
539 encoding Phh-GluCl or Phh-RDL using a Drummond nanoject II microinjector. Three to five
540 days after cRNA injection, two-electrode voltage-clamp recordings were performed with an
541 oocyte clamp OC-725C amplifier (Warner instrument) at a holding potential of -80mV or -60
542 mV to assess the expression of the GluCl or RDL channels. Currents were recorded and
543 analyzed using the pCLAMP 10.4 package (Molecular Devices). Concentration-response
544 relationships for agonists were carried out by challenging oocytes with 10 s applications of
545 increasing concentrations of compounds. The peak current values were normalized to the

546 response to 1000 μM glutamate or 100 μM GABA giving the maximum current amplitude for
547 GluCl and RDL channels, respectively. For RDL, the effect of antagonists was evaluated, by a
548 first application of each antagonist alone for 10 s, followed by the co-application with 100 μM
549 GABA for 10 s. The observed responses were normalized to the response induced by 100 μM
550 GABA alone performed prior to challenging with the antagonist. The concentration of agonist
551 required to mediate 50% of the maximum response (EC_{50}) and the concentration of antagonist
552 required to inhibit 50% of the agonist response (IC_{50}) and the Hill coefficient (nH) were
553 determined using non-linear regression on normalized data with GraphPad Prism software.
554 Results are shown as mean \pm SEM and statistical analysis were performed using One-Way
555 ANOVA with Tukey's Multiple Comparisons Test and paired Student's t-test. Chloride and
556 sodium permeabilities were conducted as described previously [51]. In brief, the reversal
557 potential of the GABA-induced currents was measured with a 1500-ms-long ramp of voltage
558 from -60 to +60 mV in standard saline recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM
559 CaCl_2 , 5 mM HEPES, pH 7.3) as well as in recording solutions containing a concentration
560 range of either chloride (NaCl replaced by sodium acetate) or sodium (NaCl replaced by
561 tetraethylammonium chloride).

562 **Materials**

563 Glutamate, GABA, fipronil, picrotoxin and ivermectin were purchased from Sigma-Aldrich.
564 Glutamate and GABA were directly dissolved in recording solution. Fipronil, picrotoxin and
565 ivermectin were first dissolved at 10-100 mM in DMSO and then diluted in recording solution
566 to the final concentrations in which DMSO did not exceed 1 %. Lotilaner (CredelioTM, Elanco,
567 USA) was a commercial formulation purchased in a local pharmacy store. Tablets containing
568 450 mg lotilaner were dissolved in DMSO to obtain a 100 mM lotilaner stock solution and
569 subsequently diluted in recording solution at a final DMSO concentration less than 0.003%.

570

571 **Acknowledgments**

572 We acknowledge the gift of the human body louse colony from Kosta Y. Mumcuoglu from the
573 Department of Microbiology and Molecular Genetics, Kuvin Center for the Study of Infectious
574 and Tropical Diseases, Hebrew University-Hadassah Medical School, Jerusalem, Israel. This
575 study was supported by the Institut National de Recherche pour l'Agriculture, l'Alimentation et
576 l'Environnement (INRAE) and the Université de Tours (annual endowment) and in part by the
577 RTR Fédération de Recherche en Infectiologie (FéRI) of the Région Centre-Val de Loire to
578 CN, CD and IDP. NL is the grateful recipient of a PhD grant from the Animal Health Division of
579 INRAE and from the Région Centre-Val de Loire, France. The funders had no role in study
580 design, data collection and analysis, decision to publish, or preparation of the manuscript.

581 References

- 582 1. Boutellis A, Abi-Rached L, Raoult D. The origin and distribution of human lice in the world.
583 *Infect Genet Evol.* 2014;23:209-17. doi: 10.1016/j.meegid.2014.01.017. PubMed PMID: 24524985.
- 584 2. Falagas ME, Matthaiou DK, Rafailidis PI, Panos G, Pappas G. Worldwide prevalence of head
585 lice. *Emerg Infect Dis.* 2008;14(9):1493-4. doi: 10.3201/eid1409.080368. PubMed PMID: 18760032;
586 PubMed Central PMCID: PMCPMC2603110.
- 587 3. Al-Shahrani SA, Alajmi RA, Ayaad TH, Al-Shahrani MA, Shaurub EH. Genetic diversity of the
588 human head lice, *Pediculus humanus capitis*, among primary school girls in Saudi Arabia, with
589 reference to their prevalence. *Parasitol Res.* 2017;116(10):2637-43. doi: 10.1007/s00436-017-5570-3.
590 PubMed PMID: 28803388.
- 591 4. Badiaga S, Brouqui P. Human louse-transmitted infectious diseases. *Clin Microbiol Infect.*
592 2012;18(4):332-7. doi: 10.1111/j.1469-0691.2012.03778.x. PubMed PMID: 22360386.
- 593 5. Liao CW, Cheng PC, Chuang TW, Chiu KC, Chiang IC, Kuo JH, et al. Prevalence of *Pediculus*
594 *capitis* in schoolchildren in Battambang, Cambodia. *J Microbiol Immunol Infect.* 2019;52(4):585-91.
595 doi: 10.1016/j.jmii.2017.09.003. PubMed PMID: 29150362.
- 596 6. Louni M, Mana N, Bitam I, Dahmani M, Parola P, Fenollar F, et al. Body lice of homeless
597 people reveal the presence of several emerging bacterial pathogens in northern Algeria. *PLoS Negl*
598 *Trop Dis.* 2018;12(4):e0006397. doi: 10.1371/journal.pntd.0006397. PubMed PMID: 29664950;
599 PubMed Central PMCID: PMCPMC5922582.
- 600 7. Ly TDA, Toure Y, Calloix C, Badiaga S, Raoult D, Tissot-Dupont H, et al. Changing
601 Demographics and Prevalence of Body Lice among Homeless Persons, Marseille, France. *Emerg Infect*
602 *Dis.* 2017;23(11):1894-7. doi: 10.3201/eid2311.170516. PubMed PMID: 29048280; PubMed Central
603 PMCID: PMCPMC5652409.
- 604 8. Nejati J, Keyhani A, Tavakoli Kareshk A, Mahmoudvand H, Saghafipour A, Khoraminasab M, et
605 al. Prevalence and Risk Factors of Pediculosis in Primary School Children in South West of Iran. *Iran J*
606 *Public Health.* 2018;47(12):1923-9. PubMed PMID: 30788308; PubMed Central PMCID:
607 PMCPMC6379608.
- 608 9. Veracx A, Raoult D. Biology and genetics of human head and body lice. *Trends Parasitol.*
609 2012;28(12):563-71. doi: 10.1016/j.pt.2012.09.003. PubMed PMID: 23069652.
- 610 10. Kirkness EF, Haas BJ, Sun W, Braig HR, Perotti MA, Clark JM, et al. Genome sequences of the
611 human body louse and its primary endosymbiont provide insights into the permanent parasitic
612 lifestyle. *Proc Natl Acad Sci U S A.* 2010;107(27):12168-73. doi: 10.1073/pnas.1003379107. PubMed
613 PMID: 20566863; PubMed Central PMCID: PMCPMC2901460.
- 614 11. Olds BP, Coates BS, Steele LD, Sun W, Agunbiade TA, Yoon KS, et al. Comparison of the
615 transcriptional profiles of head and body lice. *Insect Mol Biol.* 2012;21(2):257-68. doi:
616 10.1111/j.1365-2583.2012.01132.x. PubMed PMID: 22404397.
- 617 12. Combescot-Lang C, Vander Stichele RH, Toubate B, Veirron E, Mumcuoglu KY. Ex vivo
618 effectiveness of French over-the-counter products against head lice (*Pediculus humanus capitis* De
619 Geer, 1778). *Parasitol Res.* 2015;114(5):1779-92. doi: 10.1007/s00436-015-4363-9. PubMed PMID:
620 25716822.
- 621 13. Izri A, Uzzan B, Maignret M, Gordon MS, Bouges-Michel C. Clinical efficacy and safety in head
622 lice infection by *Pediculus humanus capitis* De Geer (Anoplura: Pediculidae) of a capillary spray
623 containing a silicon-oil complex. *Parasite.* 2010;17(4):329-35. doi: 10.1051/parasite/2010174329.
624 PubMed PMID: 21275239.
- 625 14. Diamantis SA, Morrell DS, Burkhart CN. Treatment of head lice. *Dermatol Ther.*
626 2009;22(4):273-8. doi: 10.1111/j.1529-8019.2009.01242.x. PubMed PMID: 19580574.
- 627 15. Frankowski BL. American Academy of Pediatrics guidelines for the prevention and treatment
628 of head lice infestation. *Am J Manag Care.* 2004;10(9 Suppl):S269-72. PubMed PMID: 15515631.
- 629 16. Clark JM, Yoon KS, Lee SH, Pittendrigh BR. Human lice: Past, present and future control.
630 *Pestic Biochem Phys.* 2013;106(3):162-71. doi: 10.1016/j.pestbp.2013.03.008. PubMed PMID:
631 WOS:000321805100013.

- 632 17. Downs AM, Stafford KA, Harvey I, Coles GC. Evidence for double resistance to permethrin and
633 malathion in head lice. *Br J Dermatol.* 1999;141(3):508-11. doi: 10.1046/j.1365-2133.1999.03046.x.
634 PubMed PMID: 10583056.
- 635 18. Durand R, Bouvresse S, Berdjane Z, Izri A, Chosidow O, Clark JM. Insecticide resistance in
636 head lice: clinical, parasitological and genetic aspects. *Clin Microbiol Infect.* 2012;18(4):338-44. doi:
637 10.1111/j.1469-0691.2012.03806.x. PubMed PMID: 22429458.
- 638 19. Lebwahl M, Clark L, Levitt J. Therapy for head lice based on life cycle, resistance, and safety
639 considerations. *Pediatrics.* 2007;119(5):965-74. doi: 10.1542/peds.2006-3087. PubMed PMID:
640 17473098.
- 641 20. Idriss S, Levitt J. Malathion for head lice and scabies: treatment and safety considerations. *J*
642 *Drugs Dermatol.* 2009;8(8):715-20. PubMed PMID: 19663108.
- 643 21. Eisenhower C, Farrington EA. Advancements in the treatment of head lice in pediatrics. *J*
644 *Pediatr Health Care.* 2012;26(6):451-61; quiz 62-4. doi: 10.1016/j.pedhc.2012.05.004. PubMed PMID:
645 23099312.
- 646 22. Nolan K, Kamrath J, Levitt J. Lindane toxicity: a comprehensive review of the medical
647 literature. *Pediatr Dermatol.* 2012;29(2):141-6. doi: 10.1111/j.1525-1470.2011.01519.x. PubMed
648 PMID: 21995612.
- 649 23. Guyton KZ, Loomis D, Grosse Y, El Ghissassi F, Benbrahim-Tallaa L, Guha N, et al.
650 Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate. *Lancet Oncol.*
651 2015;16(5):490-1. doi: 10.1016/S1470-2045(15)70134-8. PubMed PMID: 25801782.
- 652 24. Richardson JR, Taylor MM, Shalat SL, Guillot TS, 3rd, Caudle WM, Hossain MM, et al.
653 Developmental pesticide exposure reproduces features of attention deficit hyperactivity disorder.
654 *FASEB J.* 2015;29(5):1960-72. doi: 10.1096/fj.14-260901. PubMed PMID: 25630971; PubMed Central
655 PMCID: PMC4415012.
- 656 25. Humans IwGotEoCRt. Some Organophosphate Insecticides and Herbicides. Some
657 Organophosphate Insecticides and Herbicides. IARC Monographs on the Evaluation of Carcinogenic
658 Risks to Humans. Lyon (FR)2017.
- 659 26. Laing R, Gillan V, Devaney E. Ivermectin - Old Drug, New Tricks? *Trends Parasitol.*
660 2017;33(6):463-72. doi: 10.1016/j.pt.2017.02.004. PubMed PMID: 28285851; PubMed Central
661 PMCID: PMC446326.
- 662 27. Strycharz JP, Yoon KS, Clark JM. A new ivermectin formulation topically kills permethrin-
663 resistant human head lice (Anoplura: Pediculidae). *J Med Entomol.* 2008;45(1):75-81. doi:
664 10.1603/0022-2585(2008)45[75:aniftk]2.0.co;2. PubMed PMID: 18283945.
- 665 28. Sanchezruiz WL, Nuzum DS, Kouzi SA. Oral ivermectin for the treatment of head lice
666 infestation. *Am J Health Syst Pharm.* 2018;75(13):937-43. doi: 10.2146/ajhp170464. PubMed PMID:
667 29789316.
- 668 29. Amanzougaghene N, Fenollar F, Raoult D, Mediannikov O. Where Are We With Human Lice?
669 A Review of the Current State of Knowledge. *Front Cell Infect Microbiol.* 2019;9:474. doi:
670 10.3389/fcimb.2019.00474. PubMed PMID: 32039050; PubMed Central PMCID: PMC6990135.
- 671 30. Amanzougaghene N, Fenollar F, Diatta G, Sokhna C, Raoult D, Mediannikov O. Mutations in
672 GluCl associated with field ivermectin-resistant head lice from Senegal. *Int J Antimicrob Agents.*
673 2018;52(5):593-8. doi: 10.1016/j.ijantimicag.2018.07.005. PubMed PMID: 30055248.
- 674 31. Amanzougaghene N, Fenollar F, Nappez C, Ben-Amara A, Decloquement P, Azza S, et al.
675 Complexin in ivermectin resistance in body lice. *PLoS Genet.* 2018;14(8):e1007569. doi:
676 10.1371/journal.pgen.1007569. PubMed PMID: 30080859; PubMed Central PMCID:
677 PMC6108520.
- 678 32. Ffrench-Constant RH, Williamson MS, Davies TG, Bass C. Ion channels as insecticide targets. *J*
679 *Neurogenet.* 2016;30(3-4):163-77. doi: 10.1080/01677063.2016.1229781. PubMed PMID: 27802784;
680 PubMed Central PMCID: PMC6021766.
- 681 33. Wolstenholme AJ. Glutamate-gated chloride channels. *J Biol Chem.* 2012;287(48):40232-8.
682 doi: 10.1074/jbc.R112.406280. PubMed PMID: 23038250; PubMed Central PMCID:
683 PMC3504739.

- 684 34. Claxton DP, Gouaux E. Expression and purification of a functional heteromeric GABA
685 receptor for structural studies. *PLoS One*. 2018;13(7):e0201210. doi: 10.1371/journal.pone.0201210.
686 PubMed PMID: 30028870; PubMed Central PMCID: PMC6054424.
- 687 35. Cully DF, Paress PS, Liu KK, Schaeffer JM, Arena JP. Identification of a *Drosophila*
688 melanogaster glutamate-gated chloride channel sensitive to the antiparasitic agent avermectin. *J Biol*
689 *Chem*. 1996;271(33):20187-91. doi: 10.1074/jbc.271.33.20187. PubMed PMID: 8702744.
- 690 36. French-Constant RH, Steichen JC, Rocheleau TA, Aronstein K, Roush RT. A single-amino acid
691 substitution in a gamma-aminobutyric acid subtype A receptor locus is associated with cyclodiene
692 insecticide resistance in *Drosophila* populations. *Proc Natl Acad Sci U S A*. 1993;90(5):1957-61. doi:
693 10.1073/pnas.90.5.1957. PubMed PMID: 8095336; PubMed Central PMCID: PMC645999.
- 694 37. French-Constant RH, Rocheleau TA, Steichen JC, Chalmers AE. A point mutation in a
695 *Drosophila* GABA receptor confers insecticide resistance. *Nature*. 1993;363(6428):449-51. doi:
696 10.1038/363449a0. PubMed PMID: 8389005.
- 697 38. Casida JE, Durkin KA. Novel GABA receptor pesticide targets. *Pestic Biochem Physiol*.
698 2015;121:22-30. doi: 10.1016/j.pestbp.2014.11.006. PubMed PMID: 26047108.
- 699 39. Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner:
700 Selective inhibition of arthropod gamma-aminobutyric acid- and L-glutamate-gated chloride channels
701 and insecticidal/acaricidal activity. *Insect Biochem Molec*. 2014;45:111-24. doi:
702 10.1016/j.ibmb.2013.11.009. PubMed PMID: WOS:000331856900011.
- 703 40. Shoop WL, Hartline EJ, Gould BR, Waddell ME, McDowell RG, Kinney JB, et al. Discovery and
704 mode of action of afoxolaner, a new isoxazoline parasiticide for dogs. *Vet Parasitol*. 2014;201(3-
705 4):179-89. doi: 10.1016/j.vetpar.2014.02.020. PubMed PMID: 24631502.
- 706 41. McTier TL, Chubb N, Curtis MP, Hedges L, Inskeep GA, Knauer CS, et al. Discovery of
707 sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs. *Vet*
708 *Parasitol*. 2016;222:3-11. doi: 10.1016/j.vetpar.2016.02.019. PubMed PMID: 26961590.
- 709 42. Rufener L, Danelli V, Bertrand D, Sager H. The novel isoxazoline ectoparasiticide lotilaner
710 (Credelio (TM)): a non-competitive antagonist specific to invertebrates gamma-aminobutyric acid-
711 gated chloride channels (GABA_ACl_s). *Parasite Vector*. 2017;10. doi: ARTN 530
712 10.1186/s13071-017-2470-4. PubMed PMID: WOS:000414159300005.
- 713 43. Ozoe Y, Asahi M, Ozoe F, Nakahira K, Mita T. The antiparasitic isoxazoline A1443 is a potent
714 blocker of insect ligand-gated chloride channels. *Biochem Biophys Res Commun*. 2010;391(1):744-9. doi:
715 10.1016/j.bbrc.2009.11.131. PubMed PMID: WOS:000273624500130.
- 716 44. Sheng CW, Jia ZQ, Liu D, Wu HZ, Luo XM, Song PP, et al. Insecticidal spectrum of fluralaner to
717 agricultural and sanitary pests. *J Asia-Pac Entomol*. 2017;20(4):1213-8. doi:
718 10.1016/j.aspen.2017.08.021. PubMed PMID: WOS:000419749300023.
- 719 45. Downs AMR, Stafford KA, Coles GC. Susceptibility of British head lice, *Pediculus capitis*, to
720 imidacloprid and fipronil. *Med Vet Entomol*. 2000;14(1):105-7. doi: DOI 10.1046/j.1365-
721 2915.2000.00216.x. PubMed PMID: WOS:000086260100017.
- 722 46. Keramidis A, Moorhouse AJ, Peter PR, Barry PH. Ligand-gated ion channels: mechanisms
723 underlying ion selectivity. *Prog Biophys Mol Bio*. 2004;86(2):161-204. doi:
724 10.1016/j.pbiomolbio.2003.09.002. PubMed PMID: WOS:000223500100001.
- 725 47. Marais E, Klok CJ, Terblanche JS, Chown SL. Insect gas exchange patterns: a phylogenetic
726 perspective. *J Exp Biol*. 2005;208(23):4495-507. doi: 10.1242/jeb.01928. PubMed PMID:
727 WOS:000234414800023.
- 728 48. Eguchi Y, Ihara M, Ochi E, Shibata Y, Matsuda K, Fushiki S, et al. Functional characterization of
729 *Musca* glutamate- and GABA-gated chloride channels expressed independently and coexpressed in
730 *Xenopus* oocytes. *Insect Mol Biol*. 2006;15(6):773-83. doi: 10.1111/j.1365-2583.2006.00680.x.
731 PubMed PMID: 17201770.
- 732 49. Cornejo I, Andrini O, Niemeyer MI, Maraboli V, Gonzalez-Nilo FD, Teulon J, et al.
733 Identification and functional expression of a glutamate- and avermectin-gated chloride channel from
734 *Caligus rogercresseyi*, a southern Hemisphere sea louse affecting farmed fish. *PLoS Pathog*.

- 735 2014;10(9):e1004402. doi: 10.1371/journal.ppat.1004402. PubMed PMID: 25255455; PubMed
736 Central PMCID: PMCPMC4177951.
- 737 50. Furutani S, Ihara M, Lees K, Buckingham SD, Partridge FA, David JA, et al. The fungal alkaloid
738 Okaramine-B activates an L-glutamate-gated chloride channel from *Ixodes scapularis*, a tick vector of
739 Lyme disease. *Int J Parasitol Drugs Drug Resist*. 2018;8(2):350-60. doi: 10.1016/j.ijpddr.2018.06.001.
740 PubMed PMID: 29957333; PubMed Central PMCID: PMCPMC6039357.
- 741 51. Menard C, Folacci M, Brunello L, Charreton M, Collet C, Mary R, et al. Multiple combinations
742 of RDL subunits diversify the repertoire of GABA receptors in the honey bee parasite *Varroa*
743 *destructor*. *J Biol Chem*. 2018;293(49):19012-24. doi: 10.1074/jbc.RA118.005365. PubMed PMID:
744 30333227; PubMed Central PMCID: PMCPMC6295728.
- 745 52. Chen R, Belelli D, Lambert JJ, Peters JA, Reyes A, Lan NC. Cloning and functional expression of
746 a *Drosophila* gamma-aminobutyric acid receptor. *Proc Natl Acad Sci U S A*. 1994;91(13):6069-73. doi:
747 10.1073/pnas.91.13.6069. PubMed PMID: 8016117; PubMed Central PMCID: PMCPMC44139.
- 748 53. Yang Y, Lv J, Gui B, Yin H, Wu X, Zhang Y, et al. A-to-I RNA editing alters less-conserved
749 residues of highly conserved coding regions: implications for dual functions in evolution. *RNA*.
750 2008;14(8):1516-25. doi: 10.1261/rna.1063708. PubMed PMID: 18567816; PubMed Central PMCID:
751 PMCPMC2491475.
- 752 54. Buckingham SD, Biggin PC, Sattelle BM, Brown LA, Sattelle DB. Insect GABA receptors:
753 Splicing, editing, and targeting by antiparasitics and insecticides. *Mol Pharmacol*. 2005;68(4):942-51.
754 doi: 10.1124/mol.105.015313. PubMed PMID: WOS:000232002500003.
- 755 55. Jones AK, Sattelle DB. The cys-loop ligand-gated ion channel gene superfamily of the red flour
756 beetle, *Tribolium castaneum*. *BMC Genomics*. 2007;8:327. doi: 10.1186/1471-2164-8-327. PubMed
757 PMID: 17880682; PubMed Central PMCID: PMCPMC2064938.
- 758 56. Jones AK, Buckingham SD, Papadaki M, Yokota M, Sattelle BM, Matsuda K, et al. Splice-
759 variant- and stage-specific RNA editing of the *Drosophila* GABA receptor modulates agonist potency.
760 *J Neurosci*. 2009;29(13):4287-92. doi: 10.1523/JNEUROSCI.5251-08.2009. PubMed PMID: 19339622;
761 PubMed Central PMCID: PMCPMC6665385.
- 762 57. Taylor-Wells J, Senan A, Bermudez I, Jones AK. Species specific RNA A-to-I editing of mosquito
763 RDL modulates GABA potency and influences agonistic, potentiating and antagonistic actions of
764 ivermectin. *Insect Biochem Mol Biol*. 2018;93:1-11. doi: 10.1016/j.ibmb.2017.12.001. PubMed PMID:
765 29223796.
- 766 58. Liu F, Shi XZ, Liang YP, Wu QJ, Xu BY, Xie W, et al. A 36-bp deletion in the alpha subunit of
767 glutamate-gated chloride channel contributes to abamectin resistance in *Plutella xylostella*. *Entomol*
768 *Exp Appl*. 2014;153(2):85-92. doi: 10.1111/eea.12232. PubMed PMID: WOS:000344386700001.
- 769 59. Mermans C, Dermauw W, Geibel S, Van Leeuwen T. A G326E substitution in the glutamate-
770 gated chloride channel 3 (GluCl3) of the two-spotted spider mite *Tetranychus urticae* abolishes the
771 agonistic activity of macrocyclic lactones. *Pest Management Science*. 2017;73(12):2413-8. doi:
772 10.1002/ps.4677. PubMed PMID: WOS:000414177900003.
- 773 60. Wu SF, Mu XC, Dong YX, Wang LX, Wei Q, Gao CF. Expression pattern and pharmacological
774 characterisation of two novel alternative splice variants of the glutamate-gated chloride channel in
775 the small brown planthopper *Laodelphax striatellus*. *Pest Manag Sci*. 2017;73(3):590-7. doi:
776 10.1002/ps.4340. PubMed PMID: 27302648.
- 777 61. Xu ZF, Wu Q, Xu Q, He L. Functional Analysis Reveals Glutamate and Gamma-Aminobutyric
778 Acid-Gated Chloride Channels as Targets of Avermectins in the Carmine Spider Mite. *Toxicol Sci*.
779 2017;155(1):258-69. doi: 10.1093/toxsci/kfw210. PubMed PMID: WOS:000397041300022.
- 780 62. Atif M, Lynch JW, Keramidis A. The effects of insecticides on two splice variants of the
781 glutamate-gated chloride channel receptor of the major malaria vector, *Anopheles gambiae*. *Br J*
782 *Pharmacol*. 2020;177(1):175-87. doi: 10.1111/bph.14855. PubMed PMID: 31479507; PubMed Central
783 PMCID: PMCPMC6976876.
- 784 63. Garrood WT, Zimmer CT, Gutbrod O, Luke B, Williamson MS, Bass C, et al. Influence of the
785 RDL A301S mutation in the brown planthopper *Nilaparvata lugens* on the activity of phenylpyrazole

- 786 insecticides. *Pestic Biochem Physiol.* 2017;142:1-8. doi: 10.1016/j.pestbp.2017.01.007. PubMed
787 PMID: 29107231; PubMed Central PMCID: PMC5672059.
- 788 64. French-Constant RH, Rocheleau TA. *Drosophila* gamma-aminobutyric acid receptor gene Rdl
789 shows extensive alternative splicing. *J Neurochem.* 1993;60(6):2323-6. doi: 10.1111/j.1471-
790 4159.1993.tb03523.x. PubMed PMID: 7684073.
- 791 65. Taylor-Wells J, Hawkins J, Colombo C, Bermudez I, Jones AK. Cloning and functional
792 expression of intracellular loop variants of the honey bee (*Apis mellifera*) RDL GABA receptor.
793 *Neurotoxicology.* 2017;60:207-13. doi: 10.1016/j.neuro.2016.06.007. PubMed PMID:
794 WOS:000403133600025.
- 795 66. Jiang J, Huang LX, Chen F, Sheng CW, Huang QT, Han ZJ, et al. Novel alternative splicing of
796 GABA receptor RDL exon 9 from *Laodelphax striatellus* modulates agonist potency. *Insect Sci.* 2020.
797 doi: 10.1111/1744-7917.12789. PubMed PMID: 32293803.
- 798 67. Lindley D. Merck's new drug free to WHO for river blindness programme. *Nature.*
799 1987;329(6142):752. doi: 10.1038/329752a0. PubMed PMID: 3670379.
- 800 68. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, et al. Oral ivermectin versus
801 malathion lotion for difficult-to-treat head lice. *N Engl J Med.* 2010;362(10):896-905. doi:
802 10.1056/NEJMoa0905471. PubMed PMID: 20220184.
- 803 69. Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Assessment of topical versus oral ivermectin as a
804 treatment for head lice. *Dermatol Ther.* 2014;27(5):307-10. doi: 10.1111/dth.12144. PubMed PMID:
805 25041547.
- 806 70. Leulmi H, Diatta G, Sokhna C, Rolain JM, Raoult D. Assessment of oral ivermectin versus
807 shampoo in the treatment of pediculosis (head lice infestation) in rural areas of Sine-Saloum,
808 Senegal. *Int J Antimicrob Agents.* 2016;48(6):627-32. doi: 10.1016/j.ijantimicag.2016.07.014. PubMed
809 PMID: 27866866.
- 810 71. Yoon KS, Strycharz JP, Baek JH, Sun W, Kim JH, Kang JS, et al. Brief exposures of human body
811 lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance.
812 *Insect Mol Biol.* 2011;20(6):687-99. doi: 10.1111/j.1365-2583.2011.01097.x. PubMed PMID:
813 21895817; PubMed Central PMCID: PMC3208734.
- 814 72. Wei PL, Che WA, Wang JD, Xiao D, Wang R, Luo C. RNA interference of glutamate-gated
815 chloride channel decreases abamectin susceptibility in *Bemisia tabaci*. *Pestic Biochem Phys.*
816 2018;145:1-7. doi: 10.1016/j.pestbp.2017.12.004. PubMed PMID: WOS:000428601100001.
- 817 73. Kane NS, Hirschberg B, Qian S, Hunt D, Thomas B, Brochu R, et al. Drug-resistant *Drosophila*
818 indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and
819 ivermectin. *P Natl Acad Sci USA.* 2000;97(25):13949-54. doi: DOI 10.1073/pnas.240464697. PubMed
820 PMID: WOS:000165728800088.
- 821 74. Fuse T, Kita T, Nakata Y, Ozoe F, Ozoe Y. Electrophysiological characterization of ivermectin
822 triple actions on *Musca* chloride channels gated by L-glutamic acid and gamma-aminobutyric acid.
823 *Insect Biochem Molec.* 2016;77:78-86. doi: 10.1016/j.ibmb.2016.08.005. PubMed PMID:
824 WOS:000385321700008.
- 825 75. Wang XL, Puinean AM, O'Reilly AO, Williamson MS, Smelt CLC, Millar NS, et al. Mutations on
826 M3 helix of *Plutella xylostella* glutamate-gated chloride channel confer unequal resistance to
827 abamectin by two different mechanisms. *Insect Biochem Molec.* 2017;86:50-7. doi:
828 10.1016/j.ibmb.2017.05.006. PubMed PMID: WOS:000405055100006.
- 829 76. Nakata Y, Fuse T, Yamato K, Asahi M, Nakahira K, Ozoe F, et al. A Single Amino Acid
830 Substitution in the Third Transmembrane Region Has Opposite Impacts on the Selectivity of the
831 Parasiticides Fluralaner and Ivermectin for Ligand-Gated Chloride Channels. *Mol Pharmacol.*
832 2017;92(5):546-55. doi: 10.1124/mol.117.109413. PubMed PMID: WOS:000412893200006.
- 833 77. Yamato K, Nakata Y, Takashima M, Ozoe F, Asahi M, Kobayashi M, et al. Effects of
834 intersubunit amino acid substitutions on GABA receptor sensitivity to the ectoparasiticide fluralaner.
835 *Pestic Biochem Physiol.* 2020;163:123-9. doi: 10.1016/j.pestbp.2019.11.001. PubMed PMID:
836 31973848.

- 837 78. Little SE. Lotilaner - a novel systemic tick and flea control product for dogs. *Parasit Vectors*.
838 2017;10(1):539. doi: 10.1186/s13071-017-2471-3. PubMed PMID: 29089062; PubMed Central
839 PMCID: PMC5664799.
- 840 79. Cavalleri D, Murphy M, Seewald W, Drake J, Nanchen S. A randomised, blinded, controlled
841 field study to assess the efficacy and safety of lotilaner tablets (Credelio) in controlling fleas in client-
842 owned dogs in European countries. *Parasit Vectors*. 2017;10(1):526. doi: 10.1186/s13071-017-2479-
843 8. PubMed PMID: 29089065; PubMed Central PMCID: PMC5664837.
- 844 80. Murphy M, Garcia R, Karadzovska D, Cavalleri D, Snyder D, Seewald W, et al. Laboratory
845 evaluations of the immediate and sustained efficacy of lotilaner (Credelio) against four common
846 species of ticks affecting dogs in North America. *Parasit Vectors*. 2017;10(1):523. doi:
847 10.1186/s13071-017-2476-y. PubMed PMID: 29089057; PubMed Central PMCID: PMC5664823.
- 848 81. Miglianico M, Eldering M, Slater H, Ferguson N, Ambrose P, Lees RS, et al. Repurposing
849 isoxazoline veterinary drugs for control of vector-borne human diseases. *P Natl Acad Sci USA*.
850 2018;115(29):E6920-E6. doi: 10.1073/pnas.1801338115. PubMed PMID: WOS:000438892600031.
- 851 82. Kohler-Aanesen H, Saari S, Armstrong R, Pere K, Taenzler J, Zschiesche E, et al. Efficacy of
852 fluralaner (Bravecto chewable tablets) for the treatment of naturally acquired *Linognathus setosus*
853 infestations on dogs. *Parasit Vectors*. 2017;10(1):426. doi: 10.1186/s13071-017-2344-9. PubMed
854 PMID: 28923117; PubMed Central PMCID: PMC5604360.
- 855 83. Fisara P, Guerino F, Sun FS. Efficacy of a spot-on combination of fluralaner plus moxidectin
856 (Bravecto((R)) Plus) in cats following repeated experimental challenge with a field isolate of
857 *Ctenocephalides felis*. *Parasite Vector*. 2019;12. doi: ARTN 259
858 10.1186/s13071-019-3512-x. PubMed PMID: WOS:000468877400001.
- 859 84. Geurden T, Borowski S, Wozniakiewicz M, King V, Fourie J, Liebenberg J. Comparative efficacy
860 of a new spot-on combination product containing selamectin and sarolaner (Stronghold (R) Plus)
861 versus fluralaner (Bravecto (R)) against induced infestations with *Ixodes ricinus* ticks on cats. *Parasite*
862 *Vector*. 2017;10. doi: ARTN 319
863 10.1186/s13071-017-2259-5. PubMed PMID: WOS:000405900300003.
- 864 85. Vatta AF, King VL, Young DR, Chapin S. Efficacy of three consecutive monthly doses of a
865 topical formulation of selamectin and sarolaner (Revolution((R)) Plus/Stronghold((R)) Plus) compared
866 with a single dose of fluralaner (Bravecto((R)) for Cats) against induced infestations of
867 *Ctenocephalides felis* on cats. *Vet Parasitol*. 2019;270 Suppl 1:S52-S7. doi:
868 10.1016/j.vetpar.2019.05.004. PubMed PMID: 31133494.
- 869 86. Mumcuoglu KY, Danilevich M, Zelig O, Grinbaum H, Friger M, Meinking TL. Effects of blood
870 type and blood handling on feeding success, longevity and egg production in the body louse,
871 *Pediculus humanus humanus*. *Med Vet Entomol*. 2011;25(1):12-6. doi: 10.1111/j.1365-
872 2915.2010.00897.x. PubMed PMID: 20678099.
- 873 87. Courtot E, Charvet CL, Beech RN, Harmache A, Wolstenholme AJ, Holden-Dye L, et al.
874 Functional Characterization of a Novel Class of Morantel-Sensitive Acetylcholine Receptors in
875 Nematodes. *PLoS Pathog*. 2015;11(12):e1005267. doi: 10.1371/journal.ppat.1005267. PubMed
876 PMID: 26625142; PubMed Central PMCID: PMC4666645.
- 877 88. Boulin T, Fauvin A, Charvet CL, Cortet J, Cabaret J, Bessereau JL, et al. Functional
878 reconstitution of *Haemonchus contortus* acetylcholine receptors in *Xenopus* oocytes provides
879 mechanistic insights into levamisole resistance. *Br J Pharmacol*. 2011;164(5):1421-32. doi:
880 10.1111/j.1476-5381.2011.01420.x. PubMed PMID: 21486278; PubMed Central PMCID:
881 PMC3221097.
- 882 89. Charvet CL, Guegnard F, Courtot E, Cortet J, Neveu C. Nicotine-sensitive acetylcholine
883 receptors are relevant pharmacological targets for the control of multidrug resistant parasitic
884 nematodes. *Int J Parasitol Drugs Drug Resist*. 2018;8(3):540-9. doi: 10.1016/j.ijpddr.2018.11.003.
885 PubMed PMID: 30502120; PubMed Central PMCID: PMC6287576.

- 886 90. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides
887 from transmembrane regions. *Nat Methods*. 2011;8(10):785-6. doi: 10.1038/nmeth.1701. PubMed
888 PMID: 21959131.
- 889 91. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular architecture research tool:
890 identification of signaling domains. *Proc Natl Acad Sci U S A*. 1998;95(11):5857-64. doi:
891 10.1073/pnas.95.11.5857. PubMed PMID: 9600884; PubMed Central PMCID: PMCPMC34487.
- 892 92. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
893 *Nucleic Acids Res*. 2004;32(5):1792-7. doi: 10.1093/nar/gkh340. PubMed PMID: 15034147; PubMed
894 Central PMCID: PMCPMC390337.
- 895 93. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user interface
896 for sequence alignment and phylogenetic tree building. *Mol Biol Evol*. 2010;27(2):221-4. doi:
897 10.1093/molbev/msp259. PubMed PMID: 19854763.
- 898 94. Abongwa M, Buxton SK, Courtot E, Charvet CL, Neveu C, McCoy CJ, et al. Pharmacological
899 profile of *Ascaris suum* ACR-16, a new homomeric nicotinic acetylcholine receptor widely distributed
900 in *Ascaris* tissues. *Br J Pharmacol*. 2016;173(16):2463-77. doi: 10.1111/bph.13524. PubMed PMID:
901 27238203; PubMed Central PMCID: PMCPMC4959957.

902

903 **Figure legends**

904 **Fig. 1: Toxicity tests on lice *in vivo*.**

905 **A.** Photographs of the human body lice from the laboratory-reared colony used in this study.
906 Different life stages are represented from the left to the right: larvae in stage 1 during hatching,
907 larvae in stage 2, larvae in stage 3, female adult, male adult.

908 **B.** Adult lice (n = 44 per condition) were treated with different concentrations of lotilaner,
909 ivermectin, fipronil or picrotoxin and survival/immobilization (knockdown) rate was determined
910 throughout 24 hours. Water and 1 % DMSO were used as negative controls. The results are
911 representative of three independent experiments.

912 **C.** Nits were treated with 100µM of lotilaner or ivermectin and hatching was determined
913 throughout several days. Water and 1 % DMSO were used as negative controls. The results
914 are expressed as percentage of hatching from three independent experiments with n = 50 to
915 190 nits.

916

917 **Fig. 2: Amino acid alignments of GluCl and RDL subunit sequences of *Pediculus***
918 ***humanus humanus*, *Apis mellifera* and *Tribolium castaneum*.**

919 Predicted signal peptides in the N-terminal region are highlighted in grey. Amino acid
920 differences between Phh-GluCl-1 and Phh-GluCl-2 or between Phh-RDL-1 and Phh-RDL-2
921 sequences of *P. humanus humanus* are highlighted in red. Cys-loop domain, predicted
922 transmembrane domains TM1 to TM4 and the highly variable intracellular loop are indicated
923 by the bars. Amino acids conserved between all the sequences are highlighted in dark blue.
924 Amino-acids conserved between GluCl sequences are highlighted in light blue. Amino acids
925 conserved between RDL sequences are highlighted in pink.

926

927 **Fig. 3: Distance tree (BioNJ, Poisson) of GluCl and RDL protein sequences from insects**
928 **and acarians.**

929 The three letter prefixes in gene names Phh, Ame, Tca, Dme, Mdo and Rmi refer to the species
930 *Pediculus humanus humanus*, *Apis mellifera*, *Tribolium castaneum*, *Drosophila melanogaster*,
931 *Musca domestica* and *Rhipicephalus microplus*, respectively. Branch lengths are proportional
932 to the number of substitutions per site. Scale bar represents the number of substitutions per
933 site. The bootstrap values are indicated next to each branch. Accession numbers for
934 sequences used in the phylogenetic analysis are provided in the Methods section. Sequences

935 of *P. humanus humanus* are highlighted in blue for GluCl_s and purple for RDLs. The *A.*
936 *mellifera* alpha7 nAChR subunit sequence was used as an outgroup.

937

938 **Fig. 4: Functional expression of Phh-GluCl and Phh-RDL channels in *X. laevis* oocytes.**

939 **A.** Electrophysiological recording traces of oocytes injected with Phh-GluCl cRNA in response
940 to the application of 1 to 1000 μ M of glutamate. Oocytes were clamped at -80 mV. Application
941 times are indicated by the bar.

942 **B.** Glutamate concentration-response curve for Phh-GluCl (mean \pm SEM, n = 5 oocytes).
943 Data were normalized to the maximal effect of glutamate.

944 **C.** Electrophysiological recording traces of oocytes injected with Phh-RDL cRNA in response
945 to the application of 1 to 100 μ M of GABA. Oocytes were clamped at -60 mV. Application times
946 are indicated by the bars.

947 **D.** GABA concentration response curve for Phh-RDL (mean \pm SEM, n = 6 oocytes). Data
948 were normalized to the maximal effect of GABA.

949 **E.** Reverse potential-ion concentration relationships of oocytes expressing Phh-RDL obtained
950 from voltage-ramps in presence of GABA and using increasing concentrations of either Cl⁻ or
951 Na⁺ to analyze the selectivity of this channel.

952

953 **Fig. 5: Effects of ivermectin and lotilaner on Phh-GluCl receptor in *X. laevis* oocytes.**

954 **A.** Representative recording traces from a single oocyte expressing Phh-GluCl challenged with
955 1 mM glutamate and 10 nM ivermectin followed by 1 μ M ivermectin. The bars indicate the time
956 period of agonist application.

957 **B.** Bar chart (mean \pm SEM, n = 6 oocytes) of the response elicited by 1 μ M ivermectin (IVM)
958 normalized to and compared with the maximal response to 1 mM glutamate (Glu). *, $p < 0.05$;
959 Student's t-test

960 **C.** Representative recording traces from a single oocyte perfused with 100 μ M glutamate (Glu)
961 alone (left), with 1 μ M lotilaner prior to co-application with 100 μ M Glu (middle) and after wash
962 out (right).

963

964

965 **Fig. 6: Antagonistic effects of fipronil, picrotoxin, ivermectin and lotilaner on GABA-**
966 **elicited currents in *X. laevis* oocytes expressing Phh-RDL receptor.**


967 **A-D.** Representative current traces evoked by 100 μ M GABA with or without co-application of
968 10 μ M fipronil, picrotoxin, ivermectin and lotilaner. Application times are indicated by the bars.

969 **E.** Bar chart of the normalized current responses for 100 μ M GABA alone and in the presence
970 of 10 μ M fipronil, picrotoxin, ivermectin and lotilaner on Phh-RDL (mean \pm SEM, n = 3-9
971 oocytes). Currents have been normalized to and compared with 100 μ M GABA-elicited
972 currents. *, $p < 0.05$; One-way ANOVA with Tukey's Multiple Comparisons Test.


973 **F.** Concentration-inhibition curves for Phh-RDL for fipronil (red circles, n = 6-7), picrotoxin (blue
974 squares, n = 5-8) and lotilaner (purple triangles, n = 3-14). The responses are all normalized
975 to the response to 100 μ M GABA (mean \pm SEM, n = 3-14 oocytes).

976

A



B



C




Fig. 1

Signal peptide

Phh-GluC1-1 : -----MMPWWFSSLLFLFLTHITWEEETKVNFREREKQV-LDQILGPGR--YDARIRPSGKNGTADYTTVRRVNLLEIRSKIDDYQMEY : 84
 Phh-GluC1-2 : -----MMPWWFSSLLFLFLTHITWEEETKVNFREREKQV-LDQILGPGR--YDARIRPSGKNGT-DGPTIVHVNIFVRSISKIDDYQMEY : 83
 Ame-GluC1 : -----MWPGVLK-LLVLLTFLHPSRCTQCKVNYREKEKEV-LDNLIG-G---YDARIRPSGENAT-DGPATVRRVNLFVRSIATISDIKMEY : 80
 Tca-GluC1 : -----MYHTLIALIVHI IHVTVCTNVKINFREREKEV-LDQILGQGM--YDARIRPSGVNGT-DGPATVRRVNLFVRSIATISDIKMEY : 80
 Phh-RDL-1 : MTGRRSGRTVQDVFTSWTLVWLALATAVLKLDKSLYAQAATGGGGMLGDVNIATLDSFSVSYDKRVRPN-YGGT---PVEVGTMYVLSISSSEVLMNF : 98
 Phh-RDL-2 : MTGRRSGRTVQDVFTSWTLVWLALATAVLKLDKSLYAQAATGGGGMLGDVNIATLDSFSVSYDKRVRPN-YGGT---PVEVGTMYVLSISSSEVLMNF : 98
 Ame-RDL : -----MSFHAASWSFALLAATVALLPATHRAPFAQAATGGGGMLNDVNIATLDSFSVSYDKRVRPN-YGGP---PVEVGTMYVLSISSSEVLMNF : 89
 Tca-RDL : -----MGHSRVVWPAVLLALA---LPWAS---AGSPGAGGSYLGDVNIATLDSFSVSYDKRVRPN-YGGP---PVEVGTMYVLSISSSEVLMNF : 82

Cys-loop

Phh-GluC1-1 : SVQLTFRQWLDERLKFNDFEGRKIKYLTLD-TD-ANRVWMPDLFFSNEKEGHFNHIMPVNYIRIFPHGSVLYSIRISLTLSCPMNLKLYPLDRQVCSLRMAS : 184
 Phh-GluC1-2 : SVQLTFRQWLDERLKFNDFEGRKIKYLTLD-TD-ANRVWMPDLFFSNEKEGHFNHIMPVNYIRIFPHGSVLYSIRISLTLSCPMNLKLYPLDRQVCSLRMAS : 183
 Ame-GluC1 : SVQLTFRQWLDERLKFNDFEGRKIKYLTLD-TD-ASRVWMPDLFFSNEKEGHFNHIMPVNYIRIFPHGSVLYSIRISLTLSCPMNLKLYPLDRQVCSLRMAS : 180
 Tca-GluC1 : SVQLTFRQWLDERLKFNDFEGRKIKYLTLD-TE-ASRVWMPDLFFSNEKEGHFNHIMPVNYIRIFPHGSVLYSIRISLTLSCPMNLKLYPLDRQVCSLRMAS : 180
 Phh-RDL-1 : TLDYFRQFWDDPRLCFRKKPG-VETLSVGSDFIKNIWVDPDFFVNEKQSYPHIATTSNEFIRIHHSGSITRSIRLTIATSCPMNLQYFPMDRQLCHIEIES : 199
 Phh-RDL-2 : TLDYFRQFWDDPRLCFRKKPG-VETLSVGSDFIKNIWVDPDFFVNEKQSYPHIATTSNEFIRIHHSGSITRSIRLTIATSCPMNLQYFPMDRQLCHIEIES : 199
 Ame-RDL : TLDYFRQFWDDPRLAFAKRTG-VETLSVGSDFIKNIWVDPDFFVNEKQSYPHIATTSNEFIRIHHSGSITRSIRLTIATSCPMNLQYFPMDRQLCHIEIES : 190
 Tca-RDL : TLDYFRQFWDDPRLAFAKRTG-VETLSVGSDFIKNIWVDPDFFVNEKQSYPHIATTSNEFIRIHHSGSITRSIRLTIATSCPMNLQYFPMDRQLCHIEIES : 183

TM1

Phh-GluC1-1 : YGWTADLVFLWKVGD- DPVQVVKNLHLPRFTLEKFFTDYCNKNTNIGYSCIKVDLLFKREFSYYLIIQIYIPCCMLVIISWVSFWLDQSAVPARVSLGVTT : 285
 Phh-GluC1-2 : YGWTADLVFLWKVGD- DPVQVVKNLHLPRFTLEKFFTDYCNKNTNIGYSCIKVDLLFKREFSYYLIIQIYIPCCMLVIISWVSFWLDQSAVPARVSLGVTT : 284
 Ame-GluC1 : YGWTADLVFLWKVGD- DPVQVVKNLHLPRFTLEKFFTDYCNKNTNIGYSCIKVDLLFKREFSYYLIIQIYIPCCMLVIISWVSFWLDQSAVPARVSLGVTT : 281
 Tca-GluC1 : YGWTADLVFLWKVGD- DPVQVVKNLHLPRFTLEKFFTDYCNKNTNIGYSCIKVDLLFKREFSYYLIIQIYIPCCMLVIISWVSFWLDQSAVPARVSLGVTT : 281
 Phh-RDL-1 : FGYLMRDIRYKWNCPNSVGSNEVSLRQFKVLGHRQRAMEISLITGNYSRACEIQFVRSMGYYLIQIYIPSGLVIITSWVSFWLNRNATPARVALGVTTV : 301
 Phh-RDL-2 : FGYLMRDIRYKWNCPNSVGSNEVSLRQFKVLGHRQRAMEISLITGNYSRACEIQFVRSMGYYLIQIYIPSGLVIITSWVSFWLNRNATPARVALGVTTV : 301
 Ame-RDL : FGYLMRDIRYKWNCPNSVGSNEVSLRQFKVLGHRQRAMEISLITGNYSRACEIQFVRSMGYYLIQIYIPSGLVIITSWVSFWLNRNATPARVALGVTTV : 292
 Tca-RDL : FGYLMRDIRYKWNCPNSVGSNEVSLRQFKVLGHRQRAMEISLITGNYSRACEIQFVRSMGYYLIQIYIPSGLVIITSWVSFWLNRNATPARVALGVTTV : 285

TM2

TM3

Highly variable intracellular loop

Phh-GluC1-1 : LTMATQTSGINASLPPVSYTKAIDVWTCVCLTFVFGALLEFALVNY-ASRSDMHRENMKKQRRQCLEHAASLEA-----AADLLE-DGAT---TFAMK-- : 374
 Phh-GluC1-2 : LTMATQTSGINASLPPVSYTKAIDVWTCVCLTFVFGALLEFALVNY-ASRSDMHRENMKKQRRQCLEHAASLEA-----AADLLE-DGAT---TFAMK-- : 373
 Ame-GluC1 : LTMATQTSGINASLPPVSYTKAIDVWTCVCLTFVFGALLEFALVNY-ASRSDMHSDNIEKKYPPSETEQSTSMDL-----PSDQVEPDNSS---NFAMK-- : 371
 Tca-GluC1 : LTMATQTSGINASLPPVSYTKAIDVWTCVCLTFVFGALLEFALVNY-ASRSDMHRENMKKQRRQCLEHAASMDA-----TSDLIDTDSNA---TFAMK-- : 371
 Phh-RDL-1 : LTMITLMSSTNAALPKISYVRSIDVYLCTCFVMVFASLLEYATVGYMAKRIQMRKSRMAIQKIAEQKNKANLEAQHGPHGPIGEQDSSGP-KQTVRRKVVH : 402
 Phh-RDL-2 : LTMITLMSSTNAALPKISYVRSIDVYLCTCFVMVFASLLEYATVGYMAKRIQMRKSRMAIQKIAEQKNKANLEAQHGPHGPIGEQDSSGP-KQTVRRKVVH : 402
 Ame-RDL : LTMITLMSSTNAALPKISYVRSIDVYLCTCFVMVFASLLEYATVGYMAKRIQMRKSRMAIQKIAEQKNKANLEAQHGPHGPIGEQDSSGP-KQTVRRKVVH : 387
 Tca-RDL : LTMITLMSSTNAALPKISYVRSIDVYLCTCFVMVFASLLEYATVGYMAKRIQMRKSRMAIQKIAEQKNKANLEAQHGPHGPIGEQDSSGP-KQTVRRKVVH : 384

TM4

Phh-GluC1-1 : -PLVGHGRGDAL--AIEKARQC-----EIHMQPKRDDCCRTW--ISK-FPTRSKRIDVISRITFPPLVFALFNVVWSTYLFRED-----TBDN---- : 450
 Phh-GluC1-2 : -PLVGHGRGDAL--AIEKARQC-----EIHMQPKRDDCCRTW--ISK-FPTRSKRIDVISRITFPPLVFALFNVVWSTYLFRED-----TBDN---- : 449
 Ame-GluC1 : -PLVRQPEDTM--SVDRMQHC-----EIHMQPKRKNCCRSW--LSK-FPTRSKRIDVISRITFPPLVFALFNVVWSTYLFRED-----EONE---- : 447
 Tca-GluC1 : -PLVRHPGDPM--SLEKVRQC-----EIHMQPARPNCCRSW--LSK-FPTRSKRIDVISRITFPPLVFALFNVVWSTYLFRED-----AGES---- : 447
 Phh-RDL-1 : DPKAHSKGGTLENTING-RA-----DEEATPAPQHLIHPGKDINKLMGITPSDIDKYSRIVFPVCFVCFNLMYWIITLHISDVVADDLVFLGQDK---- : 492
 Phh-RDL-2 : DPKAHSKGGTLENTING-RA-----DEEATPAPQHLIHPGKDINKLMGITPSDIDKYSRIVFPVCFVCFNLMYWIITLHISDVVADDLVFLGQDK---- : 492
 Ame-RDL : DPKAHSKGGTLENTING-RA-----DEEATPAPQHLIHPGKDINKLYGMTSPSIDKYSRIVFPVCFVCFNLMYWIITLHISDVVADDLVFLGQDK---- : 476
 Tca-RDL : DPKAHSKGGTLENTING-RA-----DEEATPAPQHLIHPGKDINKLYGMTSPSIDKYSRIVFPVCFVCFNLMYWIITLHISDVVADDLVFLGQDK---- : 482

Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

977 **Supporting information**

978 **S1 Fig.: Comparison of insect and acari GluCl subunits.**

979 **A.** Alignment of GluCl subunit deduced amino-acid sequences from *Pediculus humanus*
980 *humanus* (Phh), *Apis mellifera* (Ame), *Rhipicephalus microplus* (Rmi) and *Tribolium*
981 *castaneum* (Tca). Predicted signal peptides in N-terminal are highlighted in grey. Amino acid
982 differences between the GluCl-1 and GluCl-2 sequences of *P. humanus humanus* are
983 highlighted in red. Amino acids conserved between all the sequences are highlighted in blue.
984 The cys-loop, transmembrane domains (TM1-TM4) and the highly variable intracellular loop
985 are indicated by the bars.

986 **B.** Distance tree (BioNJ, Poisson) of GluCl protein sequences from insects and acari. The three
987 letter prefixes in gene names Tur, Phh, Ame, Tca, Dme, Mdo, Rmi and Isc refer to the species
988 *Tetranychus urticae*, *Pediculus humanus humanus*, *Apis mellifera*, *Tribolium castaneum*,
989 *Drosophila melanogaster*, *Musca domestica*, *Rhipicephalus microplus* and *Ixodes scapularis*,
990 respectively. The tree was rooted with the *A. mellifera* alpha7 nAChR subunit as an outgroup.
991 Branch lengths are proportional to the number of substitutions per amino acid. Scale bar
992 represents the number of substitutions per site. The bootstrap values are indicated next to
993 each branch. Accession numbers for sequences used in the phylogenetic analysis are
994 provided in the Methods section. The two GluCl sequences of interest are highlighted in blue.

995

996 **S2 Fig.: Comparison of insect and acari GABA subunits.**

997 **A.** Alignment of RDL subunit deduced amino-acid sequences from *Pediculus humanus*
998 *humanus* (Phh), *Apis mellifera* (Ame), *Tribolium castaneum* (Tca) and *Rhipicephalus microplus*
999 (Rmi). Predicted signal peptides in N-terminal are highlighted in grey. Amino acid difference
1000 between the RDL-1 and RDL-2 sequences of *P. humanus humanus* are highlighted in red.
1001 Amino acids conserved between all the sequences are highlighted in blue. The cys-loop,
1002 predicted transmembrane domains (TM1-TM4) and the highly variable intracellular loop are
1003 indicated by the bars.

1004 **B.** Distance tree (BioNJ, Poisson) of GABACl protein sequence from insects and acari. The
1005 three letter prefixes in gene names Phh, Ame, Cfe, Tca, Dme, Mdo and Rmi refer to the species
1006 *Pediculus humanus humanus*, *Apis mellifera*, *Ctenocephalides felis*, *Tribolium castaneum*,
1007 *Drosophila melanogaster*, *Musca domestica* and *Rhipicephalus microplus*, respectively. The
1008 tree was rooted with the *A. mellifera* alpha7 nAChR subunit as an outgroup. Branch lengths
1009 are proportional to the number of substitutions per amino acid. Scale bar represents the
1010 number of substitutions per site. The bootstrap values are indicated next to each branch.

1011 Accession numbers for sequences used in the phylogenetic analysis are provided in the
1012 Methods section. The two RDL sequences of interest are highlighted in purple.

1013

1014 **S3 Fig.: Current traces of uninjected oocytes and oocytes injected with Phh-GluCl-2 or**
1015 **Phh-RDL-2.**

1016 **A.** Current traces of uninjected oocytes after application of glutamate and GABA at 100 μ M.
1017 The bar indicates the application time of 10 s.

1018 **B.** For Phh-GluCl-2, oocytes were clamped at -80mV and response to 100 μ M of glutamate
1019 was measured (n = 11). For Phh-RDL-2, oocytes were clamped at -60mV and response to 100
1020 μ M of GABA was measured (n = 12). The bar indicates the application time of 10 s.



1021

1022 **S4 Fig.: Antagonistic effects of 1 μ M of fipronil, picrotoxin, ivermectin and lotilaner on**
1023 **GABA-elicited currents in *X. laevis* oocytes expressing Phh-RDL receptor.**



1024 **A-D.** Representative current traces evoked by 100 μ M GABA with or without co-application of
1025 1 μ M fipronil, picrotoxin, ivermectin and lotilaner. Applications of 100 μ M GABA alone were
1026 performed before and after application of drugs. Drugs were applied for 10 s before the co-
1027 application with GABA at 100 μ M during 10 s. Application times are indicated by the bars.

1028 **E.** Bar chart showing the normalized current responses for 100 μ M GABA alone and in the
1029 presence of 1 μ M fipronil, picrotoxin, ivermectin and lotilaner on Phh-RDL (mean +/- SEM, n =
1030 3-9 oocytes). Currents have been normalized to and compared with 100 μ M GABA-elicited
1031 currents. * $p < 0.05$; One-way ANOVA.


1032




S1 Fig. Comparison of insect and acarian GluCl subunits.



S2 Fig. Comparison of insect and acarian GABA subunits.



S3 Fig. Current traces of uninjected oocytes and oocytes injected with Phh-GluCl-2 or Phh-RDL-2.



S4 Fig. Antagonistic effects of 1 μ M of fipronil, picrotoxin, ivermectin and lotilaner on GABA-elicited currents in *X. laevis* oocytes expressing Phh-RDL receptor.

1033

1034 **S1 Table: Primers used for the PCR and cloning of *P. humanus humanus* GluCl and RDL**
 1035 **subunits**

1036

Gene name	Primer name	Primer sequence
<i>GluCl</i>	Phh-GluCl-R1	CGAAATGTCAGCTGAACGCTG
	Phh-GluCl-R2	CTTCGGACAAACATGTTAACTCG
	Phh-GluCl-F0	TTGGGAAAAGCCATTGAAGAG
	Phh-GluCl-Z1R	CCAACGACGGCAATTATAAGC
	FuPhh-GluCl-pTB-XhoF	CTGGCGGCCGCTCGAGATGATGCCGTGGTGGTTCAGT
	FuPhh-GluCl-pTB-ApaR	ACCAGATCAAGCTCGGGCCCTTAATTATCTTCCGTATCTTCTCT
<i>rdl</i>	Phh-rdl-R1	GATATCGAAAGGACGTACATGGT
	Phh-rdl-R2	CGGAGATATTGACATCACCTAAC
	Phh-rdl-F0	GGTCATGATGTATCCGTCGTCA
	Phh-rdl-Z1R	AGCGTGTTTTTCGATATTTAAAAATT
	FuPhh-rdl-pTB-XhoF	CTGGCGGCCGCTCGAGAAGATGACGGGAGCACGCAGT
	FuPhh-rdl-pTB-ApaR	ACCAGATCAAGCTCGGGCCCGATGAATTTATTTATCTTGTCCCAA

1037

1038

Contributor Role	Role Definition
Conceptualization	Ideas; formulation or evolution of overarching research goals and aims. Nicolas Lamassiaude ¹ , Berthine Toubate ² , Cédric Neveu ¹ , Françoise Debierre-Grockiego ² , Claude Charvet ¹ Isabelle Dimier-Poisson ²
Data Curation	Management activities to annotate (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later reuse.
Formal Analysis	Application of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study data. Nicolas Lamassiaude ¹ , Berthine Toubate ² , Françoise Debierre-Grockiego ² , Pierre Charnet ³ , Claude Charvet ¹
Funding Acquisition	Acquisition of the financial support for the project leading to this publication. Cédric Neveu ¹ , Berthine Toubate ² , Isabelle Dimier-Poisson ²
Investigation	Conducting a research and investigation process, specifically performing the experiments, or data/evidence collection. Nicolas Lamassiaude ¹ , Berthine Toubate ² , Pierre Charnet ³ , Catherine Dupuy ² , Claude Charvet ¹
Methodology	Development or design of methodology; creation of models Nicolas Lamassiaude ¹ , Berthine Toubate ² , Cédric Neveu ¹ , Françoise Debierre-Grockiego ² , Claude Charvet ¹ Isabelle Dimier-Poisson ²
Project Administration	Management and coordination responsibility for the research activity planning and execution. Claude Charvet ¹ , Isabelle Dimier-Poisson ²
Resources	Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools. Berthine Toubate ² , Cédric Neveu ¹ , Claude Charvet ¹ , Isabelle Dimier-Poisson ²
Software	Programming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components.
Supervision	Oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team. Claude Charvet ¹ , Isabelle Dimier-Poisson ²
Validation	Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs. Nicolas Lamassiaude ¹ , Berthine Toubate ² , Pierre Charnet ³ , Cédric Neveu ¹ , Françoise Debierre-Grockiego ² , Claude Charvet ¹ , Isabelle Dimier-Poisson ²
Visualization	Preparation, creation and/or presentation of the published work, specifically visualization/data presentation. Nicolas Lamassiaude ¹ , Berthine Toubate ² , Françoise Debierre-Grockiego ²
Writing – Original Draft Preparation	Creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation). Nicolas Lamassiaude ¹
Writing – Review & Editing	Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision – including pre- or post-publication stages. Nicolas Lamassiaude ¹ , Berthine Toubate, Cédric Neveu ¹ , Françoise Debierre-Grockiego ² , Claude Charvet ¹ , Isabelle Dimier-Poisson ²

1039

1040 **Author contributions**

1041